


CEPHALOSPORANIC ACID DERIVATIVES

This invention provides novel cephalosporanic acids and esters thereof having the general formula




wherein R² is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo (lower) alkyl or acyl, R³ is hydrogen, lower alkyl, lower alkoxy, lower alkanoyloxy, and

R⁴ is hydrogen, pivaloyloxymethyl, acetoxymethyl, 1-acetoxyethyl, 5-methyl-2-oxo-1, 3-dioxolen-4-ylmethyl 1-(ethoxycarbonyloxy)ethyl, or 4-glycyloxybenzoyloxymethyl. These compounds, especially esters, are useful as broad spectrum antibiotics in the treatment and prevention of infectious diseases of mammals, and for other purposes known in the art.

Background and Prior Art


(A) Published European Patent Application No. 30,630 discloses a vast number of 7-acylamino-3-vinylcephalosporanic

acid derivatives including, inter alia, those of the formula




wherein R inter alia may be (lower)alkyl, (lower)alkenyl, (lower)alkynyl or carboxy(lower)alkyl. The compounds are prepared, inter alia, by reaction of the corresponding 3-halomethyl compound with a triarylphosphine, followed by treatment with a base and reaction with formaldehyde. In each case, the final 3-substituent is the vinyl group. There is no disclosure or suggestion of a propenyl or a substituted propenyl moiety for the 3-substituent. There is also no disclosure or suggestion of an ester as pro-drug for oral use referring to the 4-carboxylic acid moiety. That compound wherein R is $-\text{CH}_2\text{CO}_2\text{H}$ has been referred to in the literature as FK-027 and as cefvixim.

B) U.K. Patent Specification No. 1,399,086 contains a generic disclosure encompassing a vast number of cephalosporins of the formula




wherein R is hydrogen or an organic group, R^a is an etherifying monovalent organic group linked to the oxygen through a carbon atom, B is $-\text{S}-$ or $-\text{S}(=\text{O})-$, and P is an organic group. In one embodiment, P may be inter alia a vinyl group of the formula



in which R^3 and R^4 independently may be hydrogen, nitrile, (lower)alkoxycarbonyl, or substituted or unsubstituted aliphatic, cycloaliphatic, araliphatic or aromatic. However, the 2-amino-thiazol-4-yl group is not identified as a possible R substituent and there is no disclosure or suggestion about an ester as pro-drug for oral use concerning the 4-carboxylic acid thereof. U.S. Patent 3,971,778 and its divisionals Nos. 4,024,133, 4,024,137, 4,064,346, 4,033,950, 4,079,178, 4,091,209, 4,092,477 and 4,093,803 have similar disclosures.


C) U.S. Patent No. 4,307,233 discloses, inter alia, 3-vinyl cephalosporin derivatives of the formula



in which R^5 inter alia may be alkyl, vinyl, cyanomethyl or a protective group such as 2-methoxyprop-2-yl, and R^3 and R^4 are alkyl groups (optionally substituted by hydroxy, alkoxy, amino, alkylamino or dialkylamino) or phenyl groups, or R^3 and R^4 , taken together with the nitrogen to which they are attached, may form a saturated heterocyclic ring of 5 or 6 members, optionally containing another heteroatom selected from N, O and S, and optionally substituted by an alkyl group. The compounds are useful as intermediates in the preparation of 3-thiovinyl cephalosporin derivatives. There is no disclosure or suggestion of a substituted or an unsubstituted propenyl moiety for the 3-substituent and also no disclosure or suggestion concerning a pro-drug ester for oral use for the 4-carboxylic acid. Published United Kingdom Patent Application No. 2,051,062 is concordant thereto and has a similar disclosure.


D) Published European Patent Application No. 53,537 discloses, inter alia, 3-vinylcephalosporin derivatives of the

formula



in which R_5^a and R_5^b are the same or different and are hydrogen or alkyl, or taken together, form an alkylene group containing 2 or 3 carbon atoms, R_5^c is an acid protecting group, R_2 is an acid protecting group such as an ester, R_3 and R_4 are the same or different and are hydrogen, alkyl (optionally substituted by hydroxy, alkoxy, amino, alkylamino or dialkylamino) or phenyl groups, or R_3 and R_4 , taken together with the nitrogen to which they are attached, may form a saturated heterocyclic ring of 5 or 6 members, optionally containing another heteroatom selected from N, O and S, and optionally substituted by an alkyl group. The compounds are useful as intermediates in the preparation of 3-thiovinyl cephalosporin derivatives. There is no disclosure or suggestion of a substituted or an unsubstituted propenyl group for the 3-substituent and an ester of the 4-carboxylic acid for oral use.


E) U.S. Patent No. 4,307,116 discloses 3-thiovinyl-
cephalosporins of the formula




in which R^* is hydrogen, alkyl, vinyl or cyanomethyl, and R inter

alia may be one of a vast number of heterocyclic rings. There is no disclosure or suggestion of a substituted or an unsubstituted propenyl moiety for the 3-substituent and also there is no disclosure or suggestion of an ester thereof for oral use.


5 F) Published European Patent Application No. 53,074 generically discloses a vast number of 3-vinylcephalosporin derivatives of the formula



wherein R_{1a}^* (in one of several embodiments) may be




10 in which R^5 inter alia may be hydrogen, alkyl, vinyl, cyano-methyl, an oxime-protecting group such as trityl, etc., or a group of the formula



15 in which R_5^a and R_5^b are the same or different, and may be hydrogen, alkyl or, taken together, an alkylene radical of 2 or 3 carbon atoms, and R_5^c is hydrogen or an acid-protecting radical; R_{2a}^* is hydrogen or an acid-protecting radical such as methoxy-methyl;

20 R^* (in one of several embodiments) may be a methyl group substituted by a 5- or 6-membered aromatic heterocyclic ring

containing a single heteroatom, such as 2- or 3-pyridyl, 2- or 3-thienyl or 2- or 3-furyl; and R_3 is a group of the formula




5 in which R_4 may be alkyl, trihalomethyl or optionally substituted phenyl. These compounds are stated to be intermediates in the preparation of compounds in which the 3-substituent is a group of the formula



10 which are stated to have antibacterial activity. Although this patent includes the possibility of R^* being a methyl group substituted by an N-containing heterocyclic ring, in both the intermediates and final product (thus giving a heterocyclic-substituted propenyl moiety), the reference exemplifies R^* in the
15 intermediates and final product only as methyl and further in both the intermediates and final product, the propenyl group must contain a second substituent ($-O_3SR^4$ or $-SR$ respectively). There is no disclosure or suggestion of an ester thereof for oral use.


20 G) Published European Patent Application No. 53,538 discloses, inter alia, 3-vinylcephalosporin intermediates of the formula



in which n is 0 or 1, R^5 is hydrogen, alkyl, vinyl, cyanomethyl or an oxime-protecting group, and R^3 is halogen.

Complete Disclosure

This application relates to novel cephalosporin derivatives which are potent antibacterial agents and some of which may be used may be used orally. More particularly, it relates to compounds of the formula



wherein

R¹ is hydrogen or a conventional amino-protecting group

R² is hydrogen, a straight or branched chain alkyl having 1 to 4 carbon atoms, an alkenyl or alkynyl having 2 to 4 carbon atoms, cycloalkyl having 3 to 6 carbon atoms, cycloalkylalkyl having 3 to 6 ring members and 4 to 10 carbon atoms, or acyl having 2 to 4 carbon atoms,

R³ is hydrogen, lower alkyl having 1 to 3 carbon atoms, lower alkoxy having 1 to 3 carbon atoms, lower alkanoyloxy having 2 to 3 carbon atoms, and

R⁴ is hydrogen or physiologically hydrolyzable ester groups such as acetoxymethyl, 1-acetoxyethyl, pivaloyloxymethyl, 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl, 1-(ethoxycarbonyloxy)ethyl, or 4-glycyloxybenzoyloxymethyl.

Also included within the scope of the invention are the pharmaceutically acceptable acid addition salts, the metal salts (when R⁴ is H) and the solvates (including hydrates) of the compounds of Formula I, which may exist in various tautomeric forms which are also included, e.g. the 2-imino-thiazolin-4-yl form of the 2-aminothiazol-4-yl moiety.

In another aspect, this application relates to a process for the preparation of the compounds of Formula I.

As shown in the structural formula, the compounds of Formula I have the "syn" or "Z" configuration with respect to the alkoxyimino group. Because the compounds are geometric isomers, some of the "anti" isomer may also be present. This invention comprises compounds of Formula I containing at least 90% of the "syn" isomer. Preferably, the compounds of Formula I are "syn" isomers which are essentially free of the corresponding "anti" isomers.

In addition to geometric isomers possible with respect to the alkoxyimino group, the compounds of Formula I (and the intermediates VIII, XII, XIII and XIV) also form geometric (cis and trans, or Z and E) isomers about the double bond of the propenyl group at the 3-position. Both the cis ("Z") and trans ("E") isomers of these compounds are specifically included within the scope of this invention.

The pharmaceutically acceptable acid addition salts of Formula I are those in which anion does not contribute significantly to the toxicity of the salt and are compatible with the customary pharmaceutical vehicles and adapted for oral or parenteral administration. The pharmaceutically acceptable acid addition salts include the salts of Formula I with mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid and sulfuric acid, with organic carboxylic acids or organic sulfonic acids such as acetic acid, citric acid, maleic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methanesulfonic acid, p-toluene-sulfonic acid and other acids known and used in the penicillin and cephalosporin arts. Preparation of these salts is carried out by conventional techniques involving reaction of Formula Ia with the acid in a substantially equivalent amount.

Those substances of Formula I wherein R⁴ is hydrogen also form pharmaceutically acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. These salts are also part of the present invention. Suitable metal salts include

the sodium, potassium, barium, zinc and aluminum salts. The sodium or potassium salts are preferred. Amine salts prepared from amines used, for instance, with benzyl penicillin which are capable of forming stable salts with the acidic carboxyl group include trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-phenamine, N,N'-dibenzylethylenediamine, dehydroabiethylamine, N-ethylpiperidine, benzylamine and dicyclohexylamine.

The physiologically hydrolyzable esters serve as pro-drugs by being hydrolyzed in the body to yield the antibiotic per se. They are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester per se is active, or in those instances where hydrolysis occurs in the blood. Suitable esters are the acetoxymethyl, pivaloyloxymethyl, 1-acetoxyethyl, 1-pivaloyloxyethyl, 3-phthalidyl, p-glycyloxybenzoyloxymethyl, 5-methyl-1,3-dioxacyclopent-4-en-2-on-4-ylmethyl and others known in the penicillin and cephalosporin art. The most preferred esters are 1-acetoxyethyl and pivaloyloxymethyl.

The compounds of Formula I may be formulated for oral or parenteral use in a conventional manner using known pharmaceutical carriers and excipients, and they may be presented in unit dosage form or in multiple dose containers. The compositions may be in the form of tablets, capsules, solutions, suspensions or emulsions. These compounds may also be formulated as suppositories utilizing conventional suppository bases such as cocoa butter or other fatty materials. The compounds may, if desired, be administered in combination with other antibiotics including cephalosporins, penicillins and aminoglycosides.

When provided in unit dosage forms, the compositions will preferably contain from 50 to 1500 mg of the active ingredient of Formula I. The dosage of the compounds of Formula I is dependent on such factors as the weight and age of the patient, as well as the particular nature and severity of the

disease, and within the discretion of the physician. However, the dosage for adult human treatment will usually be in the range of from 500 to 5000 mg per day, depending on the frequency and route of administration. When administered intramuscularly or intravenously to an adult human, a total dosage of from 750 to 3000 mg per day, in divided doses, normally will be sufficient.

In the compounds of Formula I, hydrogen is particularly preferred for R^1 , hydrogen, acetyl or methyl for R^2 and pivaloyloxymethyl or 1-acetoxyethyl for R^4 . The most preferred compounds of the invention are listed below, and experimental details for their preparation and characterization follow. Those which are not shown by specific example are readily prepared by analogous procedures.

- 1) 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 5 2) 1-acetoxyethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 3) pivaloyloxymethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 10 4) 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 5) 1-acetoxyethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 15 6) pivaloyloxymethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 7) 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3- [(Z)-but-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 20

- 8) acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 9) 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 10) pivaloxyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 11) 4-glycyloxybenzoyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 12) 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 13) acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 14) 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate,

- 15) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 5 16) 4-glycyloxybenzoyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate,
- 17) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-pent-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 10 18) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-pent-1-en-1-yl]-3-cephem-4-carboxylate,
- 15 19) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)-acetamido]-3-[(Z)-pent-1-en-1-yl]-3-cephem-4-carboxylate,
- 20) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-pent-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 20 21) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-pent-1-en-1-yl]-3-cephem-4-carboxylate,

- 22) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)-acetamido]-3-[(E)-pent-1-en-1-yl]-3-cephem-4-carboxylate,
- 5 23) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 24) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 10 25) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 26) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 15 27) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 28) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 20

29) 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,

5 30) 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

10 31) pivaloyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 29) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 30) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 31) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 32) acetoxymethyl 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 33) 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 5 34) acetoxymethyl 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 35) 1-acetoxyethyl 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 36) pivaloyloxymethyl 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 10 37) 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 38) acetoxymethyl 7B-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,

- 39) 1-acetoxyethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,

- 5 40) pivaloyloxymethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)-acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,

- 41) 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylic acid,

- 10 42) acetoxymethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,

- 43) 1-acetoxyethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,

- 15 44) pivaloyloxymethyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,

- 45) 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylic acid,

- 20

- 46) acetoxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,
- 47) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,
- 5 48) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,
- 49) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 10 50) acetoxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,
- 51) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,
- 15 52) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate,

- 53) 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 5 54) acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 55) 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 10 56) pivaloyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic,
- 15 57) 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 58) 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 20 59) acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 60) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 5 61) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 62) 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 10 63) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid,

- 64) acetoxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 15

- 65) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,

- 66) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 20

- 67) 5-methyl-2-oxo-1,3-dioxolen-1-4-ylmethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 5 68) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 10 69) acetoxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 15 70) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 20 71) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 72) 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate,
- 25 73) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(isopropoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,

- 5 74) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(isopropoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 10 75) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(isopropoxyimino)-acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 15 76) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(allyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 20 77) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(allyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 25 78) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(allyloxyimino)-acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,
- 30 79) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(ethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,
- 80) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(ethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 81) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-ethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 5 82) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(cyclopropylmethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,

- 83) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(cyclopropylmethoxyimino)-acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 10 84) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(cyclopropylmethoxy-imino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 85) 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(propargyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid,

- 15 86) 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(propargyloxyimino)-acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 87) pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(propargyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate,

- 20

- (88) (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)-acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
- (89) 1-(ethoxycarbonyloxy)ethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)-acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.


The in vitro antibacterial activity of parent cephalosporanic acids of Formula I is shown in Table 1 in terms of geometric mean of the Minimum Inhibitory Concentrations (MIC's) which were determined by the two-fold serial agar dilution method in Mueller-Hinton agar against 25 strains of test organisms in six groups.


Table 2 shows the mouse blood levels of pro-drug esters of Formula I which were determined after oral administrations.

Table 3 shows the in vivo activity of pro-drug esters of Formula I against S. aureus Smith, E. coli Juhl, Pr. mirabilis A9900, Pr. vulgaris A9436 and Ser. marcescens A20019.

Table 4 shows the urinary recovery of various esters in the mouse.

Table 1

In vitro Activity of Cephalosporin Acids

S	Compound No. (BMY No.)	Ia			Geometric mean of MIC (mcg/ml)				
		*	R ²	R ³	GpIa (5*)	GpIb (5)	GnIa (5)	GnIb (5)	GnII (5)
	29 (28232)	Z	H	H	0.20	0.40	0.066	0.35	6.3
	37 (28266)	Z	H	OAc	0.17	0.40	0.025	0.1	1.1
	53 (28270)	Z	Ac	H	0.17	0.40	0.057	0.26	3.6
10	1 (28098)	Z	CH ₃	H	1.8	3.6	0.1	0.52	6.3
	4 (28252)	E	CH ₃	H	2.4	3.6	0.3	0.91	8.4
	7 (28154)	Z	CH ₃	CH ₃	1.8	3.1	0.30	0.80	6.3
	12 (28204)	E	CH ₃	CH ₃	1.8	4.1	0.69	1.8	14
	17 (28215)	Z	CH ₃	CH ₂ CH ₃	1.1	1.6	0.53	1.2	7.2
15	20 (28217)	E	CH ₃	CH ₂ CH ₃	1.2	2.4	0.46	0.91	6.3
	45 (28248)	Z	CH ₃	OAc	1.2	1.6	0.05	0.15	0.91
	49 (28260)	E	CH ₃	OAc	0.53	1.6	0.025	0.087	0.60
	23 (28157)	Z	CH ₃	OCH ₃	2.1	2.4	0.10	0.35	5.5
	79 (28235)	Z	CH ₂ CH ₃	H	2.1	3.1	0.30	0.91	7.3
20	73 (28233)	Z	CH(CH ₃) ₂	H	1.6	2.7	0.53	1.2	8.3
	76 (28234)	Z	CH ₂ CH=CH ₂	H	1.4	1.8	0.30	1.0	7.3
	85 28237	Z	CH ₂ C≡CH	H	1.4	1.6	0.23	0.91	14.0
	82 (28236)	Z	CH ₂ 	H	0.8	1.6	0.70	1.2	8.3
	Cefadroxil				1.4	3.6	8.3	17	>100
25	Cefaclor				0.7	4.7	0.92	11	>100

Cefvixim¹⁾
(FK-027)

4.7 12.5 0.016 3.1 3.2

Gp-Ia: Penicillin(PC)-sensitive S. aureus

Gp-Ib: PC-resistant S. aureus

5 Gn-Ia: Cephalothin(CET)-sensitive E. coli (2 strains), K. pneumoniae (1) and P. mirabilis (2)

Gn-Ib: CET-resistant E. coli (3) and K. pneumoniae (2)

Gn-II: M. morganii (1), E. cloacae (2) and S. marcescens (2)

1) -





Table 2

Mouse Blood Levels of Pro-Drug Esters



5	Compound No. (BMV No.)	75				100 mg/kg. po			20 mg/kg. po				
		R ²	R ³	R ⁴	n	C _{max} (mcg/ml)	T 1/2 (hr)	AUC (mcg hr/ml)	C _{max} (mcg/ml)	T 1/2 (hr)	AUC (mcg hr/ml)		
	30	(28271)	H	H	AX ³⁾	2	36	1.3	61	9.9	1.0	16	
	39	(28277)	H	OAc	AX	2							
	55	(28258)	Ac	H	AX	2	27	0.8	40	7.6	0.8	9.4	
10	3	(28099)	CH ₃	H	PV ¹⁾	2	33	2.2	76	6.9	2.4	18	
	2	(28191)	CH ₃	H	AX	2	50	2.3	118	21	1.9	37	
	5	(28255)	CH ₃	H	AX	H							
	10	(28155)	CH ₃	CH ₃	PV	2	21	3.0	51	6.7	4.0	14	
	8	(28225)	CH ₃	CH ₃	AM ²⁾	2				7.4	1.7	15	
	15	9	(28170)	CH ₃	CH ₃	AX	2	43	1.5	38	5.0	0.80	7.1
	11	(28231)	CH ₃	CH ₃	CBM ⁴⁾	2				5.4	2.30	13	
	14	(28205)	CH ₃	CH ₃	AX	H	55	7.0	698	12	13	239	
	18	(28216)	CH ₃	CH ₂ CH ₃	AX	2	46	2.5	98	9.1	1.9	22	
	25	(28158)	CH ₃	OCH ₃	PV	2	15	2.3	27	3.3	1.7	6.1	
20	24	(28171)	CH ₃	OCH ₃	AX	2	15	1.1	21	4.3	1.3	6.2	
		Cefaclor					26	1.2	35	8.5	0.91	8.9	
		Cefvixim					28	1.6	75	10	1.5	25	
		Cefadroxil					57	1.6	69	12	1.4	16	

1) PV = -CH₂OCOC(CH₃)₃

2) AM = -CH₂OCOCH₃

3) AX = -CH(CH₃)OCOCH₃

4) CBM = -CH₂OCO--OCOCH₂NH₂

Table 3In vivo Activity of Pro-Drug Esters in Mice

		PDs: (mg/kg, po)				
5	Compound No. (BMY No.)	<u>S. aureus</u> <u>Smith</u>	<u>E. coli</u> <u>Juhl</u>	<u>P. mira-</u> <u>bilis</u> <u>A9900</u>	<u>P. vul-</u> <u>garis</u> <u>A9436</u>	<u>S. marces-</u> <u>cens</u> <u>A20019</u>
	55 (28258)	1.8	0.36			
	3 (28099)	6.3	4.5			
	2 (28191)	8.5	1.6			
	10 (28155)	7.7	3.4	3.4	0.55	2.6
10	8 (28225)	11				
	9 (28170)	6.3	1.7	2.7	<0.39	3.6
	11 (28231)	>25				
	14 (28205)	11				
	25 (28158)	8.1				
15	24 (28171)	22.5				
	Cefaclor	0.35	0.63	3.0	3.1	>25
	Cefvixim	>25	1.6	1.2	0.68	1.1
	Cefadroxil	0.4	13	-	-	-

etc. The definition of R^{2a} also includes those same groups included in the definition of R^2 except for hydrogen.

Reaction Scheme 1 shows that the desired 7-side chain acid is introduced in the early stage. Then the group of the 3-position is converted to the substituted propenyl moiety. On the other hand, in Scheme 2 the 7-amino group of the starting Compound II is protected as a Schiff's base during most of the reaction stage and the desired 7-side chain acid is added later in the synthesis. Deblocking of both VIII and XIV gives the parent acids Ia which are converted to the pro-drug esters Ib by conventional procedures.

Reaction Scheme 1 shows two alternate means of going from Compound IV to Compound VI. One is the direct route of the reaction of the chloro derivative IV with triphenylphosphine to give the phosphonium and another is that the chloro derivative is converted to the more active iodo Compound V, then this is reacted with triphenylphosphine to give the phosphonium VI. There is no significant difference between them in their yields.

Reaction Scheme 2 shows two alternate means of going from Compound XIII to Compound Ia. One is acylation of XIII with 2-aminothiazolyl acid XX to Compound XIV followed by deblocking to Compound Ia. The other is acylation with a thiazolyl acid III having 2-N-protected-amino (such as N-tritylamino) group to give Compound VIII which is deblocked to Compound Ia.

In Reaction Schemes 1 and 2, the benzhydryl group was shown as the preferred carboxyl-protecting group. It will be appreciated by those skilled in the art that other carboxyl-protecting groups, well-known in the art, may be used. The acylating acid III or XX may be used in the form of a derivative such as its acid halide, activated ester, mixed acid anhydride, all of which are well-known in the art. Acylating acid III also may have its amino group protected by any of the common amino-protecting groups, e.g. N-trityl, N-formyl, N-t-butoxycarbonyl.

The base used to convert the phosphonium halide (VI or X) to give the phosphorylide (VII or XI) may be NaOH, Na_2CO_3 , IRA-410 (OH^-) resin, IRA (CO_3^{--}) resin, or the like, or a mixture thereof. Reaction of the ylide VII (or XI) with acetaldehyde or substituted acetaldehyde will give the 3-propenyl derivative VIII (or XII).

We have found that Compound XII from XI (Scheme 2) typically had a Z:E ratio of about 3-5:1 at the 3-(1-propenyl) configuration, while Compound VIII from VII (Scheme 1) exclusively had the Z configuration. The difference may not be in the route used, but in the conditions utilized in the Wittig reaction (VII to VIII or XI to XII). We have also found that the use of an appropriate lithium halide such as lithium chloride, lithium bromide or lithium iodide in the Wittig reaction caused improvement of the yield and purity of the Wittig reaction product VIII (or XII). The reaction is preferably carried out with 5-15 equivalents of the lithium halide. If desired the Z isomer of the Compound XIII (XIII(Z) in Scheme 3) may be converted to the corresponding E isomer (XIII(E)) by photochemical reaction in the presence of a sensitizer. The reaction is usually carried out in a solvent selected from methanol, ethanol, propanol, benzene, toluene, acetone, acetonitrile, dichloromethane, DMF, ethyl acetate, THF, pyridine in the presence of 0.5 - 10 equivalent(s) of a sensitizer selected from acetophenone, benzophenone, benzil, naphthalene, ethyl pyruvate. In the Scheme 3, R^{4a} means hydrogen or benzhydryl.


Deblocking of VIII (or XIV) to Ia is usually carried out with trifluoroacetic acid (TFA) in an adequate solvent in the presence of anisole. The acid Ia thus obtained was purified by reverse phase column chromatography utilizing a glass column containing the packing removed from a Waters' Associates PrepPAK-500/C₁₈ cartridge.

The ester Ib may be prepared in a conventional manner, for example by reacting the acid Ia or a salt thereof (such as

sodium, potassium, triethylammonium, etc.) with a halogenated compound of the formula




wherein X is chloro, bromo or iodo and R^4 is a group selected from



The reaction is carried out effectively in an inert organic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, acetone, acetonitrile, at a temperature in the range of from -10°C to $+50^\circ\text{C}$, conveniently between 0°C and 5°C . The ester Ib thus obtained is purified by conventional column chromatography by using silica gel.


Reaction Scheme 1



sodium, potassium, triethylammonium, etc.) with a halogenated compound of the formula





wherein X is chloro, bromo or iodo and R^4 is a group selected from




The reaction is carried out effectively in an inert organic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, acetone, acetonitrile, or the like, at a temperature in the range of from -10°C to +50°C, conveniently between 0°C and 5°C. The ester Ib thus obtained is purified by conventional column chromatography by using silica gel.

Reaction Scheme 1







NaI or KI



PPh₃







base




R³CH₂CHO






Reaction Scheme 2




II

PhCHO




IX

PPh₃



X







base






XI


5

10





Reaction Scheme 3



40
~~40~~
Example 1

Diphenylmethyl 7-amino-3-(1-propenyl)-3-cephem-4-carboxylate
(XIII, R³=H)

To a solution of diphenylmethyl 7-benzylideneamino-3-
5 [(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (XI)
(2.9 g, 4 mmoles) in dichloromethane (16 ml) was added 90%
acetaldehyde (10 ml, 0.2 mole). The mixture was stirred at room
temperature for 30 minutes, dried over sodium sulfate and concen-
10 trated in vacuo. The residue was dissolved in ethyl acetate (80
ml). To the solution was added isopropyl ether (160 ml) and then
silica gel (25 g). The mixture was gently agitated and filtered
to remove the solid. The filtrate was evaporated into dryness in
vacuo. To a solution of the residue in ethyl acetate (48-ml) was
15 added a mixture of Girard's reagent T (1.34 g, 8 mmoles),
methanol (40 ml) and acetic acid (2 ml). The mixture was stirred
at room temperature for 30 minutes and concentrated to ca. 10 ml.
The residue was dissolved in ethyl acetate (100 ml). The so-
lution was washed with aqueous sodium bicarbonate and water,
dried over sodium sulfate and concentrated in vacuo. The residue
20 was chromatographed on a silica gel column (50 g), which was
eluted with 1% methanol in chloroform. The eluate was collected
in 18-ml fractions. Fraction Nos. 22-40 were combined and
concentrated to give 718 mg of the 3-propenyl derivative XIII
(R³=H). (Yield 44%, E/Z=1/3).

25 TLC : R_f 0.56 (silica gel, ethyl acetate).

HPLC*: Retention time (min.) 13.2 and 15.6 (relative intensity =
3:1)

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1770, 1720.

UV : $\lambda_{\max}$ (C₂H₅OH) in nm (ϵ) 214 (20500), 222 (20800), 266
30 (4200), 273 (4200), 292 (3800).

NMR (a 1:3 mixture of E and Z isomers): δ (CDCl₃) in ppm 1.42
and 1.72 (relative intensity = 3:1) (both are dd, J=2 and 7 Hz,

CH₃), 3.37 (ABq, J=18 Hz, 2-H) and 3.52 (s, 2-H), 4.72 (d, J=4.5 Hz, 6-H), 4.97 (d, J=4.5 Hz, 7-H), 5.50 (dq, J=7 and 11 Hz, =CH-), 6.06 (dd, J=2 and 11 Hz, 3-CH=), 6.96 and 7.00 (3:1) (s, -OCHPh₂), 7.35 (s, phenyl-H).

5 *Packing: Lichrosorb RP-18 (4 x 300 mm). Mobile phase: CH₃CN-H₂O (1:1). Flow rate: 2.5 ml/min.

Example 2

Diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetamido]-3-(1-propenyl)-3-cephem-4-carboxylate (XIV, R²=CH₃, R³=H)

10 A mixture of diphenylmethyl 7-amino-3-(1-propenyl)-3-cephem-4-carboxylate (XIII, R³=H) (3.37 g, 8.3 mmoles) and 1-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetoxymethyl]benzotriazole* (2.64 g, 8.3 mmoles) in THF (70 ml) was stirred at room temperature for 30 minutes and then evaporated in vacuo. A solution of
15 the residue in ethyl acetate was washed successively with aqueous sodium bicarbonate and water, dried over anhydrous sodium sulfate and concentrated in vacuo to afford a crude product, which was dissolved in chloroform and chromatographed on a silica gel column (150 g) with 2% methanol in CHCl₃. The desired fractions
20 (TLC:silica gel, R_f 0.49, 1:2 toluene-ethyl acetate) were combined and concentrated to yield 1.95 g (40%) of XIV (R²=CH₃, R³=H) [a 1:2 mixture of E and Z isomers with respect to 3-(1-propenyl) configuration].

25 NMR (a 1:2 mixture of the E and Z isomers): δ(CDCl₃) in ppm 1.45 and 1.75 (relative intensity 2:1) (both are d, J=7 Hz, C-CH₃), 3.42 and 3.53 (2:1) (s, 2-H), 4.02 (s, OCH₃), 5.13 (d, J=4.5 Hz), 5.2-6.3 (m, 7-H and vinyl-H), 6.73 (s, thiazole-H), 6.93 (s, OCHPh₂), 7.30 (s, phenyl-H).

30 *Hoechst, Japan Kokai 54-95593 (7/28/79) and Ger. Offen 2758000 (5/7/79) (Ger. Appl. P2758000.3, 12/24/77).

42

Example 3

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(1-propenyl)-3-cephem-4-carboxylic acid (Ia, R²=CH₃, R³=H)

Compound XIV (R²=CH₃, R³=H) (1.9 g, 3.2 mmoles) was treated with trifluoroacetic acid (TFA) (5 ml) at room temperature for 40 minutes. The mixture was diluted with isopropyl ether (IPE). The resulting precipitate was collected by filtration, dissolved in formic acid and passed through a column of the packing (50 ml) of a PrepPAK cartridge (Waters), which was washed with water and eluted with 15% methanol and 20% methanol successively. Evaporation and lyophilization of 15% methanol eluate gave 206 mg (15%) of the title compound (E/Z=1/17). Estimated purity 90% (by HPLC). Mp. >180°C (slow decomp.).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1770, 1660, 1630, 1530.

UV : $\lambda_{\max}$ (pH 7 phosphate buffer) in nm (ϵ) 228 (17400), 283 (16200).

NMR : δ (D₂O + K₂CO₃) in ppm 1.70 (3H, d, J=6 Hz, C-CH₃), 3.52 (2H, ABq, J=18 Hz, 2-H), 4.03 (3H, s, OCH₃), 5.28 (1H, d, J=4.5 Hz, 6-H), 5.6-6.2 (3H, m, 7-H and vinyl-H), 7.30 (1H, thiazole-H).

HPLC : Retention time, 6.8 minutes (1:3 methanol-pH 7 phosphate buffer, 1.5 ml/min.)

Anal. Calc'd. for C₁₆H₁₇N₅O₅S₂·1/2H₂O: C, 44.44; H, 4.20;
N, 16.19; S, 14.83
Found: C, 44.37; H, 3.94;
N, 16.18; S, 14.53

Example 4

Pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃, R³=H, R⁴=PV*)

To a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(1-propenyl)-3-cephem-4-carboxylic acid (Ia, R²=CH₃, R³=H) (E/Z=1/17, 90 mg, 0.21 mmole) and potassium carbonate (44 mg, 0.32 mmole) in DMF (3 ml) was added at 0°C pivaloyloxymethyl iodide (77 mg, 0.32 mmole). The mixture was stirred at 0°C for 40 minutes, diluted with ethyl acetate (20 ml), washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo. The residue was dissolved in CHCl₃ and chromatographed on a silica gel column (silica gel:3g) by eluting with 1% methanol in CHCl₃ to yield 85 mg (75%) of the title compound. Mp. 100-104°C. Estimated purity 90% (by HPLC).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1760, 1680, 1620.

UV : $\lambda_{\max}$ (methanol) in nm (ε) 232 (17800), 287 (13500).

NMR : δ (CDCl₃) in ppm 1.23 (9H, s, C(CH₃)₃), 2.15 (3H, d, J=7 Hz, OCH₃), 3.45 (2H, s, 2-H), 4.05 (3H, s, OCH₃), 5.12 (1H, d, J=4.5 Hz, 6-H), 5.6-6.2 (5H, m, 7-H, vinyl-H and -OCH₂O-), 6.85 (1H, s, thiazole-H).

HPLC : Retention time, 8.1 minutes (1:1 CH₃CN-H₂O, 2 ml/min.)

*PV: $-\text{CH}_2\overset{\text{O}}{\parallel}\text{C}(\text{CH}_3)_3$

Example 5

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-
acetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃,
R³=H, R⁴=AX*)

5 To a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-
methoxyiminoacetamido]-3-(1-propenyl)-3-cephem-4-carboxylic acid
(190 mg, 0.45 mmole) and potassium carbonate (75 mg, 0.54 mmole)
in DMF (5 ml) was added at 5°C 1-bromoethyl acetate** (90 mg,
0.54 mmole). The mixture was stirred at 5°C for 1.5 hours and
10 diluted with ethyl acetate (20 ml). The dilute was washed
successively with water and a saturated aqueous NaCl solution,
dried over anhydrous magnesium sulfate and concentrated in vacuo.
The residue was dissolved in chloroform and chromatographed on a
silica gel column (5 g) with 1% methanol in chloroform. The
15 desired fractions were combined and concentrated. The residue
was dissolved in dioxane and lyophilized to yield 103 mg (45%) of
the title compound as its dioxane solvate. Mp. 105-110°C.
Estimated purity 85% (by HPLC).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1760(br.), 1670, 1610.

20 UV : $\lambda_{\max}$ (ethanol) in nm (ϵ) 233 (15700), 292 (12800).

NMR : δ (CDCl₃) in ppm 1.50 (3H, d, J=6 Hz, OCHCH₃), 1.65 (3H,
d, J=7 Hz, =CH-CH₃), 2.07 (3H, s, COCH₃), 3.43 (2H, s, 2-H), 3.68
(4H, s, 1/2 dioxane), 4.05 (3H, s, OCH₃), 5.10 (1H, d, J=4.5 Hz,
6-H), 5.5-6.0 (2H, m, 7-H and =CH-CH₃), 6.12 (1H, d, J=12 Hz,
25 3-CH=), 6.83 (1H, s, thiazole-H), 6.98 (1H, q, J=6 Hz, OCHO).

HPLC : Retention time, 7.5 minutes (1:1 CH₃CN-H₂O, 1 ml/min.)

*AX = -CH(CH₃)OCOCH₃

**E. Buckley and E. Whittle, Can. J. Chem., 40, 1611 (1962).

Example 6

Diphenylmethyl 7-amino-3-[(2)-1-butenyl]-3-cephem-4-carboxylate hydrochloride (XIII, R³=CH₃ hydrochloride)

To a solution of propionaldehyde (10.7 g, 18 mmoles) and lithium iodide (13.4 g, 10 mmoles) in DMF/CH₂Cl₂ (50 ml/150 ml) was added XI (7.3 g 10 mmoles) at 0°C. The mixture was allowed to stand at 5°C for 2 days and concentrated in vacuo. A solution of the residue in ethyl acetate (200 ml) was washed with water, dried over MgSO₄ and evaporated in vacuo to a syrup, which was treated with CCl₄ (200 ml) and filtered. The filtrate was concentrated to ca. 50 ml and the concentrate was stirred with 6N HCl (4 ml) at room temperature for 30 minutes. The resulting precipitate was collected by filtration and recrystallized from CHCl₃-ethyl acetate to yield 1.49 g (33%) of the title compound. Mp. 120-127°C.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1710.

UV : $\lambda_{\max}$ (methanol) in nm (ϵ) 217 (13900), 286 (7400).

NMR : δ (DMSO-d₆) in ppm 0.93 (3H, t, J=7 Hz, CH₃), 2.00 (2H, m, CH₂CH₃), 3.75 (2H, ABq, J=16 Hz, 2-H), 5.1-5.9 (3H, m, 6-H and 7-H, =CH-CH₂-), 6.33 (1H, d, J=12 Hz, 3-CH=), 6.97 (1H, s, -CHPh₂), 7.40 (10H, s, phenyl-H).

HPLC : Retention time (minutes) 10.4 and 12.0 (relative intensity = 8:1) (4:1 methanol-pH 7 phosphate buffer, 1 ml/min.)

Example 7

Diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate (XIV, R²=CH₃, R³=CH₃)

5 A suspension of diphenylmethyl 7-amino-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate hydrochloride (1.41 g, 3.1 mmoles) in ethyl acetate (20 ml) was shaken with aqueous NaHCO₃ to give a clear two-layer solution. The organic layer was separated, washed with water and then an aqueous saturated NaCl solution, and dried over MgSO₄. To the dried filtrate was added 10 1-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetoxyl]benzo-triazole (1.27 g, 4.0 mmoles), and the mixture was stirred at room temperature for 20 hours. The reaction mixture was filtered and the filtrate was washed with aqueous NaHCO₃, water and a 15 saturated NaCl solution, dried over MgSO₄ and evaporated in vacuo. The residue was chromatographed on a silica gel column (40 g) with 3:1 CHCl₃-ethyl acetate to yield 1.7 g (91%) of the title compound. TLC (silica gel):R_f 0.25 (1:1 CHCl₃-ethyl acetate).

20 IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1720, 1680, 1620.

UV : $\lambda_{\max}$ (ethanol) in nm (ϵ) 288 (12400).

25 NMR : δ (CDCl₃) in ppm 0.86 (3H, t, J=7 Hz, -CH₃), 1.90 (2H, m, CH₂CH₃), 3.45 (2H, s, 2-H), 4.06 (3H, s, OCH₃), 5.15 (1H, d, J=4.5 Hz, 6-H), 5.45 (1H, dt, J=7 and 11 Hz, =CH-CH₂-), 6.05 (1H, dd, J=4.5 and 9 Hz, 7-H), 6.17 (1H, d, J=11 Hz, 3-CH=), 6.75 (1H, s, thiazole-H), 6.97 (1H, s, CHPh₂), 7.35 (10H, s, phenyl-H), 8.08 (1H, d, J=9 Hz, CONH).

-40- 47

Example 8

7-[(2)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(2)-1-butenyl]-3-cephem-4-carboxylic acid (Ia, R²=CH₃, R³=CH₃)

A mixture of diphenylmethyl 7-[(2)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(2)-1-butenyl]-3-cephem-4-carboxylate (1.65 g, 2.65 mmoles) and anisole (0.5 ml) was treated with TFA (5 ml) at room temperature for 1 hour. The mixture was diluted with IPE. The resulting precipitate*¹ was collected by filtration and chromatographed on a column of the packing (50 ml) of a PrepPAK cartridge (Waters) with 20-30% methanol to yield 605 mg (52%) of the title compound. Estimated purity 90% (by HPLC). Mp. >160°C (grad. dec.).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1760, 1670, 1650, 1620.

UV : $\lambda_{\max}$ (pH 7 phosphate buffer) in nm (ϵ) 232 (16200), 283 (15500).

NMR : δ (D₂O + NaHCO₃) in ppm 1.00 (3H, t, J=7 Hz, CH₃), 2.00 (2H, dq, J=7 and 7 Hz, -CH₂CH₃), 3.52 (2H, ABq, J=17 Hz, 2-H), 4.02 (3H, s, OCH₃), 5.27 (1H, d, J=4.5 Hz, 6-H), 5.4-6.1 (3H, m, 7-H and -CH=CH-), 7.00 (1H, s, thiazole-H).

Anal. Calc'd. for C₁₇H₁₉N₅O₅S₂·1/2H₂O: C, 45.73; H, 4.51; N, 15.69; S, 14.36
Found: C, 45.41, H, 4.23; N, 15.35; S, 14.21

*¹HPLC: Retention time (minutes), 5.0 and 6.4 (relative intensity = 8:1) (3:7 methanol-pH 7 phosphate buffer, 2 ml/min.)

Example 9

Pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃, R³=CH₃, R⁴=PV*)

Pivaloyloxymethyl iodide (162 mg, 0.67 mmole) was added at 0°C to a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylic acid (197 mg, 0.45 mmole) and K₂CO₃ (93 mg, 0.67 mmole) in DMF (4 ml). The mixture was stirred at 0-5°C for 1 hour and diluted with ethyl acetate (30 ml). The dilute was washed with water and a saturated NaCl solution, dried over anhydrous MgSO₄ and evaporated in vacuo. The residue was chromatographed on a silica gel column (5 g) with 1% methanol in CHCl₃. The desired fractions were combined and concentrated in vacuo. The residue was dissolved in dioxane and lyophilized to afford 242 mg (97%) of the dioxane solvate of the title compound. Silica gel TLC:Rf 0.25 (1:1 CHCl₃-ethyl acetate). Estimated purity 85% (by HPLC). Mp. 90-95°C.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1750, 1670.

UV : $\lambda_{\max}$ (ethanol) in nm (ϵ) 233 (15300), 285 (11300).

NMR : δ (CDCl₃) in ppm 0.97 (3H, t, J=7 Hz CH₂CH₃), 1.23 (9H, s, C(CH₃)₃), 2.03 (2H, dq, J=7 and 7 Hz, -CH₂CH₃), 3.43 (2H, s, 2-H), 3.67 (4H, s, 1/2 dioxane), 4.02 (3H, s, OCH₃), 5.10 (1H, d, J=4.5 Hz, 6-H), 5.3-6.3 (5H, m, 7-H, -CH=CH- and -OCH₂O-), 6.82 (1H, s, thiazole-H), 7.97 (1H, d, J=8 Hz, CONH).

HPLC : Retention time, 10.0 minutes (1:1 CH₃CN-H₂O, 2 ml/min.)

Anal. Calc'd. for C₂₃H₂₉N₅O₇S₂·1/2C₄H₈O₂: C, 50.41; H, 5.58; N, 11.76; S, 10.76

Found: C, 49.94; H, 5.57; N, 11.56; S, 10.76

*PV = $-\text{CH}_2\text{OCOC}(\text{CH}_3)_3$

Example 10

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-
acetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃,
R³=CH₃, R⁴=AX*)

To a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylic acid (1.55 g, 3.54 mmol) and K₂CO₃ (636 mg, 4.6 mmol) in DMF (4 ml) was added at 5°C 1-bromoethyl acetate (769 mg, 4.6 mmol). The mixture was stirred at 5°C for 1 hour, diluted with ethyl acetate (300 ml), washed with water, dried over anhydrous MgSO₄ and concentrated in vacuo. The residue was dissolved in chloroform and chromatographed on a silica gel column (50 g) with 1% methanol in CHCl₃. The desired fractions were combined and concentrated to a small volume. The residue was triturated with isopropyl ether to give 1.29 g (70%) of the title compound as the isopropyl ether solvate. Estimated purity 90% (by HPLC). Mp. 103-110°C (dec.).

IR : ν_{max} (KBr) in cm⁻¹ 1770(br.), 1670, 1620.

UV : λ_{max} (ethanol) in nm (ε) 233 (14300), 288 (11000).

NMR : δ (CDCl₃) in ppm 1.00 (3H, t, J=7 Hz, -CH₂CH₃), 1.12 (12H, d, J=6 Hz, isopropyl ether CH₃), 1.53 (3H, d, J=5 Hz, OCHCH₃), 1.95 (2H, m, CH₂CH₃), 2.08 (3H, s, COCH₃), 3.43 (2H, s, 2-H), 3.62 (2H, m, isopropyl ether CH), 4.08 (3H, s, OCH₃), 5.13 (1H, d, J=4.5 Hz, 6-H), 5.2-6.2 (3H, m, 7-H and -CH=CH-), 6.87 (1H, s, thiazole-H), 7.00 (1H, q, J=5 Hz, -CHCH₃).

HPLC : Retention time, 10.8 minutes (1:1 CH₃CN-H₂O, 1 ml/min.)

Anal. Calc'd. for $C_{21}H_{25}N_5O_7S_2 \cdot C_6H_{14}O$: C, 51.83; H, 6.28;
N, 11.19; S, 10.25
Found: C, 51.62; H, 6.07;
N, 11.16; S, 10.05

5 *AX = $-\text{CH}(\text{CH}_3)\text{OCOCH}_3$

Example 11

Diphenylmethyl 7-[(Z)-2-methoxyimino-2-(2-tritylaminothiazol-4-yl)acetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylate (VIII, $R^{2a}=\text{CH}_3$, $R^3=\text{OCH}_3$).

10 A solution of diphenylmethyl 7-[(Z)-2-methoxyimino-2-(2-tritylaminothiazol-4-yl)acetamido]-3-triphenylphosphonio-
methyl-3-cephem-4-carboxylate iodide (1.19 g, 1 mmole) in CH_2Cl_2
(30 ml) was shaken with 1N NaOH (5 ml) for 2 minutes. The
organic layer was separated, washed with water and a saturated
15 aqueous NaCl solution, dried over anhydrous sodium sulfate and
filtered. To the filtrate was added isopropyl alcohol (15 ml)
and methoxyacetaldehyde (7.41 mg, 10 mmoles). The mixture was
stirred at room temperature overnight and evaporated to dryness
in vacuo. The residue was dissolved in CHCl_3 and chromatographed
20 on a silica gel column (20 g) with 1:20 ethyl acetate-toluene as
eluant to afford 570 mg (66%) of the title compound.

IR : ν_{max} (KBr) in cm^{-1} 1775, 1720, 1670, 1525, 1175.

25 NMR : δ ($\text{CDCl}_3 + \text{D}_2\text{O}$) in ppm 3.24 (3H, s, OCH_3), 3.3-3.8 (4H, m, S- CH_2 and OCH_2), 4.13 (3H, s, NOCH_3), 5.15 (1H, d, $J=4.5$ Hz, 6-H), 5.98 (1H, d, $J=4.5$ Hz, 7-H), 6.3 (1H, d, $J=11$ Hz, vinyl-H), 6.8 (1H, s, thiazole-H), 6.98 (1H, s, CHPH_2), 7.1-7.5 (25H, phenyl-H).

HPLC : Retention time 13.6 minutes (3:1 $\text{CH}_3\text{CN}-\text{H}_2\text{O}$, 1 ml/min.)

Example 12

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylic acid (Ia, $R^2=CH_3$, $R^3=OCH_3$)

A solution of diphenylmethyl 7-[(Z)-2-methoxyimino-2-(2-tritylaminothiazol-4-yl)acetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylate (550 mg, 0.64 mmole) in anisole-TFA (0.5 ml/5 ml) was allowed to stand at room temperature for 50 minutes and diluted with isopropyl ether to give a precipitate, which was collected by filtration and washed with IPE. The solid was dissolved in methanol and chromatographed on a column of the packing (40 ml) of a PrepPAK cartridge (Waters) with 30% methanol as eluant to afford 104 mg (36%) of the title compound. Mp. 155-159°C (dec.). Estimated purity 90% (by HPLC).

IR : ν_{max} (KBr) in cm^{-1} 1765, 1660, 1630, 1530, 1040.

UV : λ_{max} (methanol) in nm (ϵ) 234 (16600), 287 (14500).

NMR : δ (DMSO- d_6 + D_2O) in ppm 3.19 (3H, s, OCH_3), 3.83 (3H, s, OCH_3), 5.17 (1H, d, $J=5$ Hz, 6-H), 5.4-5.8 (1H, m, vinyl-H), 5.72 (1H, d, $J=5$ Hz, 7-H), 6.27 (1H, d, $J=12$ Hz, vinyl-H), 6.72 (1H, s, thiazole-H).

HPLC : Retention time 9.6 minutes (1:3 methanol-pH 7 phosphate buffer, 1 ml/min.)

Anal. Calc'd. for $C_{17}H_{19}N_5O_6 \cdot H_2O$: C, 43.30; H, 4.49; N, 14.85; S, 13.60

Found: C, 43.04; H, 4.09; N, 14.59; S, 13.89

Example 13

Pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃, R³=OCH₃, R⁴=PV)

Esterification of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylic acid (226 mg, 0.5 mmole) in a similar manner to that described in Example 9 gave the title compound (97 mg, 34%). Mp. 100-102°C. Estimated purity 90% (by HPLC, 1:1 methanol-pH 7 phosphate buffer).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1775, 1750, 1670, 1530, 1370, 1120.

UV : $\lambda_{\max}$ (methanol) in nm (ϵ) 232 (16600), 289 (13500).

NMR : δ (DMSO-d₆ + D₂O) in ppm 1.18 (9H, s, 3 x CH₃), 3.19 (3H, s, OCH₃), 3.57 (2H, br., SCH₂), 3.85 (3H, s, OCH₃), 5.23 (1H, d, J=5 Hz, 6-H), 5.4-5.9 (4H, m, 7-H, OCH₂O and vinyl-H), 6.24 (1H, d, J=12 Hz, vinyl-H), 6.74 (1H, s, thiazole-H).

Example 14

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃, R³=OCH₃, R⁴=AX)

Esterification of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-methoxy-1-propenyl]-3-cephem-4-carboxylic acid (300 mg, 0.66 mmole) with 1-bromoethyl acetate in a similar manner to that described in Example 10 gave the title compound (154 mg, 43%). Mp. 102-105°C (dec.). Estimated purity 95% (by HPLC, 1:1 CH₃CN-pH 7 phosphate buffer).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1775-1760, 1670, 1530, 1375.

UV : $\lambda_{\max}$ (methanol) in nm (ϵ) 232 (15900), 288 (13000).

NMR : δ ($\text{CDCl}_3 + \text{D}_2\text{O}$) in ppm 1.51 (3H, d, $J=5$ Hz, CHCH_3), 2.07 (3H, s, COCH_3), 3.29 (3H, s, CH_2OCH_3), 3.45 (2H, br., S- CH_2), 3.87 (2H, d, $J=7$ Hz, $=\text{CHCH}_2\text{O}$), 4.04 (3H, s, NOCH_3), 5.09 (1H, d, $J=5$ Hz, 6-H), 5.55-5.9 (1H, m, vinyl-H), 5.97 (1H, d, $J=5$ Hz, 7-H), 6.8 (1H, d, $J=12$ Hz, vinyl-H), 6.83 (1H, s, thiazole-H), 6.97 (1H, q, $J=5$ Hz, OCHCH_3).

Example 15

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylic acid (Ia, $R^2=\text{CH}_3$, $R^3=\text{CH}_3$, E isomer)

A mixture of the diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate which was obtained in Example 7 (7.6 g, 1.3 mmoles), TFA (25 ml) and anisole (5 ml) was stirred at 5°C for 1 hour and diluted with isopropyl ether. The resulting precipitate was collected by filtration, dissolved in formic acid and purified by preparative HPLC (Waters, System 500, PrepPAK-500/ C_{18}) with 40% methanol. The eluate was monitored by analytical HPLC and grouped in two fractions, which were evaporated in vacuo to give 0.94 g of the Z isomer of Ia ($R^2=\text{CH}_3$, $R^3=\text{CH}_3$) and 1.65 g of a mixture of the Z isomer and the corresponding E isomer. The mixture was dissolved in formic acid and chromatographed on a column of the packing (50 ml) of a PrepPAK cartridge (Waters) with 20-30% methanol to yield 0.22 g (4%) of the E isomer together with 0.90 g of the Z isomer. Estimated purity 90% (by HPLC). Mp. >170°C (grad. dec.).

IR : ν_{max} (KBr) in cm^{-1} 1760, 1660.

UV : λ_{max} (pH 7 phosphate buffer) in nm (ϵ) 232 (15400), 292 (19400).

NMR : δ ($\text{D}_2\text{O} + \text{NaHCO}_3$) in ppm 1.18 (3H, t, $J=7$ Hz, CH_2CH_3), 2.30 (2H, m, CH_2CH_3), 3.83 (2H, s, 2-H), 4.15 (3H, s, OCH_3), 5.37

(1H, d, J=5 Hz, 6-H), 5.92 (1H, d, J=5 Hz, 7-H), 5.9-6.4 (1H, m, =CHCH₂), 5.66 (1H, d, J=16 Hz, 3-CH=), 7.18 (1H, s, thiazole-H).

HPLC : Retention time 6.4 minutes (3:7 methanol-pH 7 phosphate buffer, 2.0 ml/min.)

5

Example 16

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylate (Ib, R²=CH₃, R³=CH₃, R⁴=AX E isomer)

10

To a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylic acid (130 mg, 0.3 mmole) and K₂CO₃ (55 mg, 0.4 mmole) in DMF (2.5 ml) was added at 5°C 1-bromoethyl acetate (67 mg, 0.4 mmole). The mixture was stirred at 5°C for 1 hour, diluted with ethyl acetate (25 ml), washed successively with water and an aqueous NaCl solution, dried over anhydrous MgSO₄ and concentrated in vacuo. The residue was dissolved in chloroform and chromatographed on a silica gel column with 1% methanol in CHCl₃. The desired fractions were combined and concentrated in vacuo to yield 77 mg (49%) of the title compound. Estimated purity 90% (by HPLC). Mp. 110-115°C.

15

20

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1760 (br.), 1670, 1510.

UV : $\lambda_{\max}$ (methanol) in nm (ε) 232 (15100), 298 (17000).

25

NMR : δ (CDCl₃) in ppm 1.05 (3H, t, J=7 Hz, CH₂CH₃), 1.54 (3H, d, J=6 Hz, CHCH₃), 2.08 (3H, s, COCH₃), 2.0-2.4 (2H, m, -CH₂CH₃), 3.57 (2H, s, 2-H), 4.05 (3H, s, OCH₃), 5.07 (1H, d, J=5 Hz, 6-H), 5.8-6.3 (2H, m, 7-H and =CH-CH₂-), 6.86 (1H, s, thiazole-H), 6.8-7.1 (2H, m, OCH and 3-CH=).

HPLC : Retention time, 7.7 minutes (1:1 CH₃CN-H₂O, 1.5 min/ml.)

Example 17

Acetoxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate
 (Ib. $R^2 = CH_3$, $R^3 = CH_3$, $R^4 = CH_2OCOCH_3$, Z isomer)

To a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylic acid (300 mg, 0.69 m mole) and K_2CO_3 (95 mg, 0.69 m mole) in dry DMF (3 ml) was added dropwise at 0°C a solution of bromomethyl acetate (105 mg, 0.69 m mole) in dry DMF (0.25 ml) and the mixture was stirred at 0°C for 15 minutes. To the mixture was added again a solution of bromomethyl acetate (105 mg, 0.69 m mole) in dry DMF (0.25 ml). The reaction mixture was stirred for another 30 minutes and diluted with ethyl acetate (20 ml). The dilute was washed with water and a saturated NaCl solution, dried over anhydrous Na_2SO_4 and evaporated to dryness. The residue was dissolved in methanol and passed through a column of the packing (40 ml) of a PrepPAK cartridge (Waters), which was washed with water and then eluted with 50% methanol. The elute was monitored by HPLC. The desired fractions were collected and evaporated to give 96 mg (27%) of the title compound. Estimated purity 90% (by HPLC). M.p. 149-152°C.

IR: ν_{max} (KBr) in cm^{-1} 1780, 1660, 1535, 1375, 1170, 1045.

UV: λ_{max} (methanol) in nm (ϵ) 231 (17000), 239(13100).

NMR: δ ($CHCl_3 + D_2O$) in ppm 0.99 (3H, t, $J=7.2$ Hz, CH_3), 2.11 (3H, s, $COCH_3$), 1.75-2.5 (2H, m, CH_2CH_3), 3.45 (2H, s, S- CH_2), 4.05 (3E, s, OCH_3), 5.11 (1H, d, $J=4.5$ Hz, 6-H), 5.81 (2H, s, OCH_2O), 5.99 (1H, d, $J=4.5$ Hz, 7-H), 6.18 (1H, d, $J=12$ Hz, 3-CH=), 6.76 (1H, s, thiazole-H).

HPLC : Retention time, 6.3 minutes (3:2 CH₃CN -
PH 7 phosphate buffer).

Anal. Calcd. for C₂₀H₂₃N₅O₇S₂·1/2H₂O : C, 46.32 ;
H, 4.66 ; N, 13.50 ; S, 12.37. Found : C, 46.51 ;
5 H, 4.44 ; N, 13.34 ; S, 12.25.

Example 18

4-[N-(t-Butoxycarbonyl)glycyloxy]benzoyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate (Ib, R² = CH₃, R³ = CH₃, R⁴ = BOC-GBM*)

A solution of chloromethyl 4-[N-(t-butoxycarbonyl)glycyloxybenzoate (584 mg, 1.7 m moles) in acetone (10 ml) was stirred with sodium iodide (1.28 g, 8.5 m moles) at room temperature for 6 hr. The separated sodium chloride was removed by filtration. The filtrate was concentrated in vacuo. The residue was dissolved in dimethylformamide (10 ml) and added at -20°C to a mixture of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylic acid (437 mg, 1 m mole) and potassium carbonate (207 mg, 1.5 m mole) in dimethylformamide (5 ml). The mixture was stirred at 0°C for 1 hr, diluted with ethyl acetate (50 ml), washed successively with water and an aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was chromatographed on a silica gel column (20 g) eluting with 1:1 toluene-ethyl acetate to yield 533 mg (76%) of the title compound. TLC (silica gel):R_f 0.16 (1:1 toluene-ethyl acetate). M.p. 110-117°C.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1770, 1740, 1670.

UV : $\lambda_{\max}$ (methanol) in nm (ε) 237 (26700), 257(11800)

NMR : δ (CDCl₃ + D₂O) in ppm 0.90 (3H, t, J=7 Hz, CH₂CH₃), 1.48 (9H, s, C(CH₃)₃), 2.00 (2H, dq, J=7 and 7 Hz, CH₂CH₃), 3.43 (2H, s, 2-H), 3.98 (3H, s, OCH₃), 4.13 (2H, s, CH₂NH), 5.10 (1H, d, J=4.5 Hz, 6-H), 5.50 (1H, dt, J=11 and 7 Hz), 5.9-6.3 (4H, m, 7-H, vinyl-H and OCH₂O), 6.52 (1H, s, thiazole-H), 7.17 and 8.06 (2H each, d, J=8 Hz, benzene-H).

* BOC-GBM = $-\text{CH}_2\text{OCO}-\langle \text{C}_6\text{H}_4 \rangle-\text{OCOCH}_2\text{NHCOOC}(\text{CH}_3)_3$

Example 19

4-Glycyloxybenzoyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-acetamido]-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate dihydrochloride (Ib. $R^2 = CH_3$, $R^3 = CH_3$, $R^4 = GEM^*$, hydrochloride)

A mixture of the N-(t-butoxycarbonyl) derivative (349 mg, 0.5 mmole) obtained in Example 18, anisole (3 drops) and 2N hydrochloric acid in ethyl acetate (2.5 ml) was stirred at 5° C for 15 min. The resulting

- 5 precipitate was collected by filtration and dissolved in methanol (3 ml). After filtration, ethyl acetate (39 ml) was added to the filtrate. The resulting precipitate was collected by filtration to yield 166 mg (46%) of the title compound. M. p. > 160°C (dec.).
- 10 Estimated purity 90% (by HPLC).

IR : ν_{max} (KBr) in cm^{-1} 1780, 1745, 1670, 1630.

UV : λ_{max} (methanol) in nm (ϵ) 235 (27200), 287 (12900).

- 15 NMR : δ (DMSO- d_6) in ppm 0.78 (3H, t J=7 Hz, CH_2CH_3), 2.00 (2H, m, CH_2CH_3), 3.52 (2H, s, 2-H), 3.90 (3H, s, OCH_3), 4.05 (2H, s, CH_2NH), 5.22 (1H, d, J=5 Hz, 6-H), 5.5-6.2 (5H, m, 7-H, vinyl-H x 2 and OCH_2O), 6.88 (1H, s, thiazole-H), 7.35 and 8.00 (2H each, d, J=B Hz, benzene-H).

- 20 Anal. Calcd. for $C_{27}H_{28}N_6O_9S_2 \cdot 2HCl \cdot 1/2H_2O$: C, 44.63; H, 4.30 ; N, 11.57 ; S, 8.82 ; Cl, 9.76. Found : C, 44.60; E, 4.34 ; N, 11.13 ; S, 8.46 ; Cl, 9.18.
- HPLC : Retention time, 5.2 minutes (3:2 CH_3CN-H_2O , 1 ml/min.)



Example 20

Diphenylmethyl 7-amino-3-(1-pentenyl)-3-cephem-4-carboxylate (XIII, $R^3 = CH_2CH_3$)

To a cooled and stirred solution of 8.7 g (0.1 mole) of anhydrous lithium bromide in 50 ml of DMF was added in one portion a solution of 7.3 g (0.01 mole) of the ylide (II) in 250 ml of methylene chloride. To the solution
5 was added 30 ml of n-butyraldehyde and the mixture was stirred at room temperature for 24 hours. After concentrating to 50 ml, the residue was extracted with 300 ml of ethyl acetate. The extract was washed with water and a saturated NaCl solution, and dried with
10 anhydrous $MgSO_4$. Wako-gel (C-100, 10 g) and active carbon (1 g) were added. The mixture was filtered and the filtrate was concentrated to 100 ml. To the concentrate was added 5 g (0.03 mole) of Girard T in 100 ml of methanol containing 5 ml of acetic acid and
15 the mixture was stirred at room temperature for 30 min. After being evaporated to dryness, the residue was extracted with 300 ml of ethyl acetate. The extract was washed successively with water, an aqueous sodium bicarbonate solution, water and a saturated NaCl
20 solution and dried with anhydrous $MgSO_4$. After evaporating to dryness, the residue was chromatographed on a silica gel column (Merck Kieselgel 60, 120 g) by eluting with toluene-ethyl acetate (5 : 1). The desired fractions collected by monitoring with TLC were evaporated
25 to dryness to give 1.78 g (41%) of title compound as a foamy solid.

NMR : δ ($CDCl_3$) in ppm 0.7-2.0 (7H, m, $CH_2 \times 2$ & C- CH_3), 3.28 (1H, d, $J=18$ Hz, 2-H), 3.58 (1H, d, $J=18$ Hz, 2-H), 4.75 (1H, d, $J=4.5$ Hz, 6-H), 5.01 (1H, d, $J=4.5$ Hz, 7-H), 5.2-5.7 (1H, m, $CH=C$), 6.12 (1H, d, $J=11$ Hz, 3-CH=O), 7.00 (1H, s, $CHPh_2$), 7.2-7.6 (10H, m, phenyl-H).

Example 21

Diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(1-pentenyl)-3-cephem-4-carboxylate
 (XIV. $R^2 = CH_3$, $R^3 = CH_2CH_3$)

A mixture of 1.7 g (3.9 m mole) of XIII ($R^3 = CH_2CH_3$) and 1.24 g (3.9 m mole) of 1-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetoxyl]-benzotriazole in 150 ml of ethyl acetate was stirred at room temperature for 20
 5 hours and the mixture was evaporated to dryness. The residue was chromatographed on a silica gel column (Merck Kieselgel 60, 60 g) by eluting with chloroform and 1% methanol in chloroform successively. The desired fractions, eluted with chloroform-methanol and monitored
 10 by silica gel TLC (1:15 MeOH- $CHCl_3$, Rf 0.50), were collected and evaporated to dryness. The residue was triturated with ether-isopropyl ether to give 1.94 g (85%) of the title compound, melting at 115-120°C (dec.)

IR : ν_{max} (KBr) in cm^{-1} 1775, 1720, 1670, 1610,
 15 1530, 1380, 1220, 1180, 1030.

UV : λ_{max} (methanol) in nm (ϵ) 290(14000).

NMR : δ ($CDCl_3$) in ppm 0.6-2.1 (7H, m, $CH_2 \times 2$ & CH_3),
 3.42 (2H, br-s, 2-H), 4.04 (3H, s, OCH_3), 5.15 (1H, d,
 J = 4.5 Hz, 6-H), 5.3-5.8 (3H, m, $CH=C$ & NH_2), 6.02 (1H,
 20 d-d, J=4.5 & 8 Hz, 7-H), 6.15 (1H, d, J=11 Hz, 3-CH=C),
 6.80 (1H, s, thiazole, H), 6.98 (1H, s, $CHPh_2$), 7.2-7.5
 (10H, m, phenyl-H), 8.0 (1H, d, J=8 Hz, NH).

Example 22

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]
-3-[(Z)-1-pentenyl]-3-cephem-4-carboxylic acid (Ia,
 $R^2 = CH_3$, $R^3 = CH_2CH_3$, Z isomer)

A mixture of 2.5 g (4.27 m moles) of XIV ($R^2 = CH_3$, $R^3 = CH_2CH_3$), 2.5 ml of anisole and 7.5 ml of trifluoroacetic acid was stirred at room temperature for 10 min and concentrated to 3 ml. The residue was diluted with
 5 100 ml of isopropyl ether to give 2 g of trifluoroacetate of the title compound (a 5:1 mixture of Z and E isomers). The crude product was dissolved in aqueous methanol and the solution was chromatographed on a column of the packing of PrepPAK C_{18} cartridge (Waters, 300 ml) by
 10 eluting successively with water, 10% methanol, 20% methanol, 30% methanol and 40% methanol. The eluate was monitored with HPLC. The Z isomer-containing fractions of the 40% methanol eluate were collected and evaporated to dryness and the residual solid was
 15 dissolved in methanol and filtered. To the filtrate was added 200 ml of isopropyl ether and the resulting solid was collected by filtration, washed with isopropyl ether and dried in vacuo over P_2O_5 to give 695 mg (39%) of the product, which was 90% pure by HPLC. M. p.
 20 150-155 (dec.).

IR : ν_{max} (KBr) in cm^{-1} 1770, 1670, 1630, 1530, 1370, 1180, 1040.

UV : λ_{max} (pH phosphate buffer) in nm (ϵ) 229 (16000), 283 (15000).

25 NMR : δ ($D_2O + Na_2CO_3$) in ppm 1.01 (3H, t, $J=7$ Hz, CH_2CH_3), 1.3-1.7 (2H, m, $CH_2CH_2CH_3$), 2.0-2.3 (2H, m, $=CH-CH_2-CH_2$), 3.46 (1H, d, $J=18$ Hz, 2-H), 3.76 (1H, d, $J=18$ Hz, 2-H), 4.15 (3H, s, OCH_3), 5.38 (1H, d, $J=4.5$ Hz, 6-H), 5.5-5.9 (1H, m, $CH=C$), 5.92 (1H, d, $J=4.5$ Hz, 7-H), 6.09 (1H, d, $J=11$ Hz, 3- $CH=C$), 7.16 (1H, s, thiazole-H).

Anal. Calcd. for $C_{18}H_{21}N_5O_5S_2 \cdot 1/2H_2O$: C, 46.94 ;
H, 4.82 ; N, 15.21 ; S, 13.92. Found : C, 46.93,
47.04 ; H, 4.66, 4.71 ; N, 15.00, 15.00 ; S, 13.34,
13.36.

HPLC : Retention time, 9.9 minutes (2:3 MeOH - pH 7
phosphate buffer, 1 ml/min.)

Example 23

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]
-3-[(E)-1-pentenyl]-3-cephem-4-carboxylic acid (Ia, R²
= CH₃, R³ = CH₂CH₃, E isomer)

The E isomer-containing fractions of the 40% methanol eluate (cf. Example 22) were collected and evaporated to dryness to give 455 mg of a mixture of cis and trans isomers (1:1). The crude product was
 5 rechromatographed on a column of the packing of PrepPAK C₁₈ cartridge (Waters, 300 ml) by eluting with 35% methanol and monitoring with HPLC. The desired fractions containing the trans isomer were collected and concentrated to 10 ml and lyophilized to give
 10 89 mg (5%) of the product which was 75% pure by HPLC. M. p. 180°C (grad. dec.).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1770, 1660, 1630, 1530, 1380, 1040.

UV : $\lambda_{\max}$ (pH phosphate buffer) in nm (ϵ) 228
 15 (17000), 292 (22000).

NMR : δ (D₂O + Na₂CO₃) in ppm 1.05 (3H, t, J=7 Hz, CH₂CH₃), 1.2-1.8 (2H, m, CH₂CH₂CH₃), 2.1-2.5 (2H, m, =CH-CH₂CH₂), 3.81 (2H, s, 2-H), 4.16 (3H, s, OCH₃), 5.37 (1H, d, J=4.5 Hz, 6-H), 5.91 (1H, d, J=4.5 Hz, 7-H), 5.9-6.3 (1H, m, CH=C), 6.67 (1H, d, J=16 Hz, 3-CH=C), 7.17 (1H, s, thiazole-H).

HPLC : Retention time, 12.3 minutes (2:3 MeOH-pH 7 phosphate buffer, 1 ml/min.)

Example 24

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy-iminoacetamido]-3-[(Z)-1-pentenyl]-3-cephem-4-carboxylate
(Ib, $R^2 = CH_3$, $R^3 = CH_2CH_3$, $R^4 = AX$, Z isomer)

To a stirred mixture of Ia ($R^2 = CH_3$, $R^3 = CH_2CH_3$, Z isomer) (225 mg, 0.5 m mole) and 69 mg (0.5 m mole) of potassium carbonate in 5 ml of DMF was added at 0-5°C a solution of 84 mg (0.5 m mole) of 1-acetoxyethyl bromide in 1 ml of DMF and the mixture was stirred at room temperature for 30 min. To the mixture was added again a solution of 84 mg (0.5 m mole) of the bromide in 1 ml of DMF and

the mixture was stirred at 5-10°C for 30 min. Then, the mixture was extracted with 100 ml of ethyl acetate. The extract was washed with an aqueous sodium bicarbonate solution, water and a saturated NaCl solution successively and dried with $MgSO_4$. After evaporating to dryness, the oily residue was chromatographed on a silica gel column (Kieselgel 60, 30 g) by eluting with chloroform and 1% methanol in chloroform successively, and monitoring with TLC and HPLC. The desired fractions eluting with 1% methanol in chloroform were collected and evaporated to dryness. The residue was triturated with ether-n-hexane to give 91 mg of the title compound. The crude side fractions were re-chromatographed similarly to give additional 63 mg of the product. The total yield was 154 mg (57%). Est'd purity 80% by HPLC. M. p. 100-110°C (dec.).

IR : ν_{max} (KBr) in cm^{-1} 1765, 1670, 1610, 1530, 1380, 1240, 1210, 1180, 1100, 1070, 1040.

UV : λ_{max} (methanol) in nm (ϵ) 233(17000), 290(13000).

65

~~66~~- ~~66a~~ -

NMR : δ (CDCl₃) in ppm 0.90 (3H, t, J=7 Hz, CH₂CH₃), 1.2-1.8 (5H, n, CHCH₃ & CH₂CH₂CH₃), 1.8-2.1 (2H, m, =CH-CH₂CH₂), 2.06 (3H, s, COCH₃), 3.43 (2H, br-s, 2-H), 4.05 (3H, s, OCH₃), 5.08 (1H, d, J=4.5 Hz, 6-H), 5.32

(2H, br-s, NH_2), 5.5-5.7 (1H, m, $\text{CH}=\text{C}$), 5.94 (1H, d-d, $J=8$ & 4.5 Hz, 7-H), 6.13 (1H, d, $J=11$ Hz, 3- $\text{CH}=\text{C}$), 6.84 (1H, s, thiazole-H), 6.97 (1H, q, $J=7$ Hz, $\text{CH}-\text{CH}_3$), 7.48 (1H, d, $J=8$ Hz, NH).

HPLC : Retention time, 8.1 minutes (7:3 MeOH-pH 7 phosphite buffer, 1 ml/min).

Example 25

Diphenylmethyl 7-[2-(2-tritylaminothiazol-4-yl)-2-(Z)-isopropoxyiminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (VIII, $R^{2a} = CH(CH_3)_2$, $R^3 = H$)

To a mixture of 2-(2-tritylaminothiazol-4-yl)-2-(Z)-isopropoxyiminoacetic acid (III, $R^{2a} = CH(CH_3)_2$: 754 mg, 1.60 m moles) and dichloromethane (7 ml) was added phosphorus pentachloride (332 mg, 1.60 m moles) at -10°C. The mixture was allowed to stand for 20 min at the same temperature and added dropwise to a solution of diphenylmethyl 7-amino-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate hydrochloride (XIII, $R^3 = H$: 443 mg, 1 m mole) and N,O-bis(trimethylsilyl)acetamide (0.74 ml, 4.4 m moles) in dichloromethane (5 ml) at -10°C. The reaction mixture was allowed to stand for 30 min. at the same temperature and poured into ice-water. Extraction of the mixture with ethyl acetate followed by evaporation of the extracts under reduced pressure gave the crude product as an oil, which was chromatographed on a column of silica gel (eluted with chloroform) to give 419 mg (49%) of VIII ($R^2 = CH(CH_3)_2$, $R^3 = H$) as an amorphous powder.

IR : ν_{max} (KBr) in cm^{-1} 1780, 1720, 1680.

* R. Bucourt et al., Tetrahedron 34, 2233 (1978)

Example 26

7-[2-(2-Aminothiazol-4-yl)-2-(Z)-isopropoxyimino-
acetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylic
acid (Ia, $R^2 = CH(CH_3)_2$, $R^3 = H$)

5 A mixture of VIII ($R^{2a} = CH(CH_3)_2$, $R^3 = H$: 400 mg, 0.47 m mole) and 85% formic acid (2 ml) was stirred for 3 hr at room temperature and to the mixture was added hydrochloric acid (0.08 ml). The mixture was
10 stirred for additional 4 hr and evaporated under reduced pressure. The residue was triturated with isopropyl ether to give the crude product, which was purified by column chromatography on C-18 silica gel (eluent, 30% aq. MeOH) followed by concentration
under reduced pressure to give the title compound as needles. Yield 70 mg (33%). M. p. 170-175°C (dec.).
Est'd purity 90%.

IR : ν_{max} (KBr) in cm^{-1} 1760, 1660, 1540, 1380.

15 UV : λ_{max} (pH 7 phosphate buffer) in nm ($B_1^1 \%$)
232 (370), 284 (357).

NMR : δ ($D_2O + NaHCO_3$) in ppm 1.50 (6H, d, $J=6$ Hz, i-Pr), 1.76 (3H, d, $J=6$ Hz, $=CH-CH_3$), 3.65 (2H, ABq, $J=18$ Hz, 2-H), 5.42 (1H, d, $J=4$ Hz, 6-H), 5.80-6.40 (3H, m, vinyl-H, 7-H), 7.15 (1H, s, thiazole-H).

Example 27

Diphenylmethyl 7-[2-(2-tritylaminothiazol-4-yl)-2-(Z)-allyloxyiminoacetamido]-3-((Z)-1-propenyl)-3-cephem-4-carboxylate (2) (VIII, $R^{2a} = CH_2CH=CH_2$, $R^3 = H$)

To a mixture of 2-(2-tritylaminothiazol-4-yl)-2-(Z)-allyloxyiminoacetic acid (III, $R^{2a} = CH_2CH=CH_2$) (750 mg, 1.60 m moles) and dichloromethane (5 ml) was added phosphorus pentachloride (332 mg, 1.60 m moles) at -10°C. The mixture was allowed to stand for 20 min at the same temperature and added dropwise to a solution of diphenylmethyl 7-amino-3-((Z)-1-propenyl)-3-cephem-4-carboxylate hydrochloride (XIII, $R^3 = H$: 443 mg, 1 m mole) and N,O-bis(trimethylsilyl)acetamide (0.74 ml, 4.4 m moles) in dichloromethane (5 ml) at -10°C. The reaction mixture was allowed to stand for 30 min. at the same temperature and poured into ice-water. Extraction of the mixture with chloroform and evaporation of the extracts under reduced pressure gave the crude product as an oil, which was chromatographed on a column of silica gel (eluted with chloroform) to give 517 mg (95%) of VIII ($R^{2a} = CH_2CH=CH_2$, $R^3 = H$) as an amorphous powder.

IR : ν_{max} (KBr) in cm^{-1} 1780, 1720, 1680.

* R. Bucourt et al., Tetrahedron 34, 2233 (1978)

Example 28

7-[2-(2-Aminothiazol-4-yl)-2-(Z)-alloxyiminoacetamido]-3-((Z)-1-propenyl)-3-cephem-4-carboxylic acid (Ia, R² = CH₂CH=CH₂, R³ = H)

A mixture of VIII (R^{2a} = CH₂CH=CH₂, R³ = H: 810 mg, 0.95 m mole) and 85% formic acid (2 ml) was stirred for 3 hr at room temperature and to the mixture was added hydrochloric acid (0.1 ml). The mixture was stirred for 3 hr and evaporated under reduced pressure.

Trituration of the residue with isopropyl ether gave the crude product, which was dissolved in a small amount of methanol and chromatographed on a column of C-18 silica gel (eluted with 30% aq. MeOH). The eluate was concentrated under reduced pressure and freeze-dried to give 215 mg (50%) of the title compound as an amorphous powder. M.p. 140°C (dec.). Est'd purity 80%.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1770, 1660, 1620.

UV : $\lambda_{\max}$ (pH 7 phosphate buffer) in nm (E₁¹ cm⁻¹ %) 232 (378), 285 (326).

NMR : δ (D₂O + NaHCO₃) in ppm 1.78 (3H, d, J=6 Hz, C=CH-CH₃), 3.62 (2H, ABq, J=18 Hz, 2-H), 5.50-6.30 (7H, m, vinyl-H, 6,7-H), 7.18 (1H, s, thiazole-H).

Example 29

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(Z)-ethoxyiminoacetamidol
-3-((Z)-1-propenyl)-3-cephem-4-carboxylic acid (Ia, R²
= C₂H₅, R³ = H)

- To a solution of (Z)-2-(2-*N*-tritylaminothiazol-4-yl)-2-ethoxyiminoacetic acid* (III, R^{2a} = C₂H₅) (458 mg, 1.0 m mole) and 1-hydroxybenzotriazole (135 mg, 1.0 m mole) in a mixture of dichloromethane (20 ml) and tetrahydrofuran (7 ml) at room temperature was added dicyclohexylcarbodiimide (210 mg, 1.0 m mole).
- The mixture was stirred for 80 min, filtered and the filtrate was concentrated to dryness. The residue was dissolved in tetrahydrofuran (10 ml) and diphenylmethyl 3-propenyl-3-cephem-4-carboxylate hydrochloride (XIII, R³ = H: 443 mg, 1 m mole) and sodium bicarbonate (84 mg, 1 m mole) were added. Water (10 drops) was added and the resulting solution was stirred at room temperature for 12 hr. The reaction mixture was diluted with ether and filtered. The filtrate was concentrated to give an oil. The oil was chromatographed on silica gel (230-400 mesh), eluting with 2:1 hexane-ethyl acetate to give the acylation product (VIII, R^{2a} = C₂H₅, R³ = H) (400 mg). This was dissolved in formic acid (1.6 ml), stirred vigorously for 60 min and 12 N HCl (50 μ l) was added. The mixture was stirred at room temperature for 3 hr, diluted with water (2 ml) and toluene (20 ml) and evaporated at 30°C to dryness. The residue was triturated with isopropyl ether, the resulting precipitates were collected and washed with isopropyl ether. The solid was chromatographed on C-18 silica gel, eluting with 3:7 methanol-water to give the title compound as an amorphous solid, 100 mg (23%), M.p. 158°C (dec.). Est'd purity 90% (based on HPLC).

72

IR : $\nu_{\max}$ (KBr) in cm^{-1} 3600-2600, 1765, 1660,
1620, 1530, 1385, 1355, 1035.

UV : $\lambda_{\max}$ (MeOH) in nm (ϵ) 235 (16100),
256 (13800).

NMR : δ ($D_2O + NaHCO_3$) in ppm 1.45 (3H, t, $J=7$ Hz),
1.77 (3H, d, $J=6$ Hz), 3.45 and 3.75 (2H, ABq, $J=18$ Hz),
4.40 (2H, q, $J=7$ Hz), 5.40 (1H, d, $J=5$ Hz), 5.75-6.20
(3H, m), 7.13 (1H, s).

*R. Bucourt et al., Tetrahedron 34, 2233 (1978)

Example 30

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-cyclopropylmethoxy-
iminoacetamido]-3-((Z)-1-propenyl)-3-cephem-4-
carboxylic acid (Ia, $R^2 = \text{CH}_2-\triangle$, $R^3 = 2$)

5 To a solution of (Z)-2-(2-*N*-tritylaminothiazol-4-yl)-2-cyclopropylmethyliminoacetic acid* (III, $R^{2a} = \text{CH}_2-\triangle$) (484 mg, 1.0 m mole) and 1-hydroxybenzo-
triazole (135 mg, 1.0 m mole) in a mixture of di-
10 chloromethane (20 ml) and tetrahydrofuran (7 ml) at room temperature was added dicyclohexylcarbodiimide (210 mg, 1.0 m mole). The mixture was stirred for 80 min, filtered and the filtrate was concentrated to dryness. The residue was dissolved in tetrahydrofuran (10 ml) and diphenylmethyl 3-propenyl-3-cephem-4-
15 carboxylate hydrochloride (XIII, $R^3 = \text{H}$) (443 mg, 1.0 m mole) and sodium bicarbonate (84 mg, 1.0 m mole) were added. Water (10 drops) was added and the resulting solution was stirred at room temperature for 12 hr. The reaction mixture was diluted with ether and
20 filtered. The filtrate was concentrated to give an oil. The oil was chromatographed on silica gel (230-400 mesh), eluting with 2:1 hexane-ethyl acetate to give the acylation product (VIII, $R^{2a} = \text{CH}_2-\triangle$, $R^3 = \text{H}$) (500 mg). This was dissolved in formic acid (2.0 ml), stirred
25 vigorously for 60 min at room temperature and 12N HCl (50 μl) was added. The mixture was stirred at room temperature for 3 hr, diluted with water (2 ml) and toluene (20 ml) and evaporated at 30 °C to dryness. The residue was triturated with isopropyl ether and the
30 resulting precipitates were collected and washed with isopropyl ether. The solid was chromatographed on C-18 silica gel, eluting with 4:6 methanol-water to give the title compound as an amorphous solid, 80 mg (19 %), M. p. 150 °C (dec.). Est'd purity 85% (based on HPLC).

35 IR : ν_{max} (KBr) in cm^{-1} 3600-2600, 1765, 1660, 1620, 1530, 1350, 1025, 1010.

ν : λ_{max} (MeOH) in nm (e) 236 (17200), 256 (14400).

75
21

NMR : δ ($D_2O + NaHCO_3$) in ppm 0.25-0.85 (4H, m),
1.20-1.60 (1H, m), 1.75 (3H, d, $J=6$ Hz), 3.45 and 3.75
(2H, ABq, $J=18$ Hz), 4.17 (2H, d, $J=7$ Hz), 5.40 (1H, d,
 $J=5$ Hz), 5.75-6.20 (3H, m), 7.14 (1H, s).

*Glaxo, Japan Kokai 59-106492 (6/20/84)

Example 31

Diphenylmethyl 7-[2-(2-tritylaminothiazol-4-yl)-2-(propargyloximino-acetamido)]-3-((Z)-1-propenyl)-3-cephem-4-carboxylate (VIII, $R^{2a} = CH_2C\equiv CH$, $R^3 = H$)

- 5 To a cooled solution of 750 mg (1.65 m moles) of diphenylmethyl 7-amino-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate hydrochloride (XIII, $R^3 = H$) and 1.05 ml (5 m moles) of N,O-bis(trimethylsilyl)acetamide in 17 ml of dry methylene chloride was added a solution of 750 mg
- 10 (1.65 m moles) of 2-tritylaminothiazol-4-yl-2-(2-propargyloxyimino)acetic acid* (III, $R^{2a} = CH_2C\equiv CH$) and 415 mg (2.0 m moles) of phosphorus pentachloride in 17 ml of dry methylene chloride, and the mixture was stirred for 1 hr at room temperature. The reaction mixture was
- 15 poured into an aqueous $NaHCO_3$ solution (30 ml) and diluted with 60 ml of ethyl acetate. The organic layer was washed with water (30 ml x 2) and brine (20 ml), dried over $MgSO_4$ and concentrated under reduced pressure. The oily residue was chromatographed on a column of
- 20 silica gel (Walo gel-200, 20 g) which was eluted with $CHCl_3$. Fractions containing the desired product were combined and concentrated under reduced pressure to give 90.5 mg (97 %) of the title compound. M. p. 155 °C (dec.).
- IR : ν_{max} (KBr) in cm^{-1} 3280, 2120, 1780, 1720,
- 25 1670.

*US Patent 4,294,960 (10/13/81)

Example 32

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(propargyloxyimino-acetamido)]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylic acid
(Ia, $R^2 = CH_2C\equiv CH$, $R^3 = H$)

5 A solution of 900 mg (1.18 m moles) of VIII ($R^{2a} = CH_2C\equiv CH$, $R^3 = H$) in 3 ml of 85 % formic acid was stirred at room temperature for one hour. To the reaction mixture was added 0.3 ml of conc. HCl and the suspension was stirred for 4 hr at ambient temperature. The mixture was filtered and washed with a small portion of formic acid and
 10 concentrated under reduced pressure. The residue was chromatographed on a column of reverse phase silica gel which was taken out of a PrepP K-500/C₁₈ cartridge column (Waters). The column was eluted with water and 30 % MeOH-water, successively. Fractions containing the desired
 15 product were combined and lyophilized to afford 105 mg (22 %) of the title compound.

IR : ν_{max} (KBr) in cm^{-1} 3400, 3280, 1770, 1670, 1630.

UV : λ_{max} (pH 7 phosphate buffer) in nm (ϵ) 229 (17000), 285 (14200).

20 NMR : δ ($D_2O + NaHCO_3$) in ppm 1.75 (3H, d, $J=6$ Hz, $CH=CH-CH_3$), 3.61 (2H, ABq, 2-H), 4.98 (2H, s, $O-CH_2-C=CH$), 5.39 (1H, d, $J=5$ Hz, 6-H), 5.80 (1H, m, $CH=CH-CH_3$), 5.92 (1H, d, $J=5$ Hz, 7-H), 6.08 (1H, d, $J=11$ Hz, $CH=CHCH_3$), 7.22 (1H, s, thiazole-5H).

Example 33

Diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyimino-acetamido]-3-((Z)-1-propenyl)-3-cephem-4-carboxylate (VIII. $R^{2a} = \text{Tr}$. $R^3 = \text{H}$)

- 5 To a mixture of 2-(2-tritylaminothiazol-4-yl)-2-(Z)-trityloximino-acetic acid (III, $R^{2a} = \text{Tr}$) (873 mg, 1.30 m moles) and dichloromethane (5 ml) was added phosphorus pentachloride (297 mg, 1.43 m moles) at -5°C . The mixture was allowed to stand for 20 min at the same
- 10 temperature and added dropwise to a solution of diphenylmethyl 7-amino-3-(1-propenyl)-3-cephem-4-carboxylate hydrochloride (XIII, $R^3 = \text{H}$: 443 mg, 1 m mole) and N,O-bis(trimethylsilyl)acetamide (0.74 ml, 4.4 m moles) in dichloromethane (5 ml) at -5°C . The reaction
- 15 mixture was allowed to stand for 20 min. at the same temperature and poured into ice-water. Extraction of the mixture with ethyl acetate and evaporation of the extracts under reduced pressure gave the crude product as an oil, which was chromatographed on a column of
- 20 silica gel (eluted with chloroform) to give the title compound as an amorphous powder. Yield 510 mg (48 %).

IR : ν_{max} (nujol) in cm^{-1} 1780, 1720, 1680.

*R. Bucourt et al., *Tetrahedron* 34, 2233 (1978)

Example 34

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylic acid (Ia. $R^2 = R^3 = R^4 = H$)

A mixture of VIII ($R^{2a} = Tr, R^3 = H$) (810 mg, 0.76 m mole) and 85 % formic acid (2 ml) was stirred for 1 hr at room temperature. To the reaction mixture was added hydrochloric acid (0.1 ml). The mixture being stirred for 2 hr and evaporated under reduced pressure, the residue was triturated with isopropyl ether to give the crude product, which was chromatographed on a column of C-18 silica gel (eluted with 20 % aq. MeOH). The eluate was concentrated under reduced pressure and freeze-dried to give the title compound as an amorphous powder. Yield 109 mg (35 %). M. p. 170 °C (dec.). Est'd purity 75%.

IR : ν_{max} (KBr) in cm^{-1} 1770, 1760, 1630.

UV : λ_{max} (pH 7 phosphate buffer) in nm ($E_{1\%}^{1\text{cm}}$)

225 (450), 282 (370).

NMR : δ ($D_2O + NaHCO_3$) in ppm 1.78 (3H, d, $J=6$ Hz, $CH=CH-CH_3$), 3.64 (2H, ABq, $J=18$ Hz, 2-H), 5.40 (1H, d, $J=4$ Hz, 6-H), 5.70-6.25 (3H, m, 7-H, vinyl-H), 7.14 (1H, d, thiazole-H).

Example 35

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxy-iminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate
(Ib, $R^2=R^3=H, R^4=AX$)

- 5 To an ice-cooled and stirred solution of Ia
($R^2=R^3=H$, Example 34) (270 mg, 0.66 m mole) in dry DMF
(2 ml) were added sodium carbonate (105 mg, 0.99 m mol)
and a solution of 1-acetoxyethyl bromide (397 mg, 2.38 m
mol) in DMF (0.6 ml) in three portions at 15-minute
10 intervals. The reaction was monitored by TLC (Merck
Kieselgel 60 F₂₅₄, 10:1 MeCN-H₂O). The mixture was
stirred for additional 30 minutes, showing three major
spots at R_f 0.11, 0.58 and 0.75. After dilution with ethyl
acetate (50 ml), the resulting precipitate was filtered off,
15 and the filtrate washed with water (x 3) and subsequently
with saturated aqueous sodium chloride, and dried over
magnesium sulfate. The filtrate was evaporated to dryness
in vacuo and the residue was dissolved in a small amount of
chloroform. The solution was chromatographed on a
20 Kieselgel 60 column (20 g), which was eluted with CHCl₃ and
then with a 1 : 20 mixture of MeOH and CHCl₃. Fractions
showing a spot of R_f 0.58 by TLC were combined and concentra-
ted to a small volume. To the concentrated was added
isopropyl ether to give a precipitate, which was collected
25 by filtration to afford 61 mg (19 %) of the desired
acetoxyethyl ester. M.p. 120-125 °C. Estimated purity 75 %
by HPLC.*

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1765, 1665, 1610, 1530, 1375.

UV : $\lambda_{\max}$ (EtOH) in nm (ϵ) 223 (19000), 264 (12000),
30 285 (12000).

NMR : δ (CDCl₃) in ppm 1.50 (3H, d, J=50 Hz, CHCH₃),
1.65 (3H, d, J=6.0 Hz, =CHCH₃), 2.07 (3H, s, COCH₃), 3.45
(2H, br, SCH₂), 5.08 (1H, d, J=5.5 Hz, 6-H), 5.5-6.0 (2H,
m, 7-H & =CH), 6.15 (1H, d, J=10 Hz, 3-CH=), 6.96 (2H, m,
35 thiazole-H & OCHCH₃)

*Packing: TSK gel 120 T (4x250 mm)

Mobile phase: CH₃CN/pH 6 phosphate buffer (2/3)

Example 36

1-Acetoxyethyl 7-[(Z)-2-(2-Aminothiazol-4-yl)-2-acetoxy-iminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=Ac, R³=H, R⁴=AX)

5 To a stirred mixture of Ia (R²=R³=H) (200 mg, 0.49 m mole) and K₂CO₃ (34 mg, 0.24 m mole) in dry DMF (5 ml) was added at 0 °C a solution of 1-acetoxyethyl bromide (81 mg, 0.49 m mole) in dry DMF (0.1 ml). Potassium carbonate and the bromide were added to the mixture
10 additional 4 times at 45-minute intervals. The reaction mixture was monitored by HPLC (Lichrosorb RP-18 4x300 mm, 4:1 MeCN-H₂O). After the addition, the mixture was stirred for 30 min. The reaction mixture showing a major peak at 4.5 min (retention time) was diluted with AcOEt (40 ml), washed with water (x 3) and a saturated NaCl
15 solution, dried over MgSO₄ and evaporated to a small volume. The concentrate was chromatographed on a Kieselgel 60 (8 g) column by eluting with a 1:20 mixture of MeOH-CHCl₃. The eluate was monitored by HPLC and the fractions showing a
20 peak of a retention time at 4.5 min were combined and concentrated to ca. 2 ml. To the concentrate was added isopropyl ether (20 ml) to give 190 mg (72 %) of the title compound as an isopropyl ether solvate. Est'd purity 85 %.

25 IR : $\nu_{\max}$ (KBr) in cm⁻¹ 3280 (w), 1770 (s), 1680 (m), 1540 (m), 1215 (s).

UV : $\lambda_{\max}$ (MeOH) in nm (ϵ) 231 (17600), 293 (9800).

30 NMR : δ (CDCl₃ + D₂O) in ppm 1.5 (3H, d, J=6 Hz, OCHCH₃), 1.65 (3H, d-d, J=7 & 1 Hz, =CHCH₃), 2.05 (3H, s, COCH₃), 2.2 (3H, s, COCH₃), 3.44 (2H, br, SCH₂), 5.1 (1H, d, J=5 Hz, 6-H), 5.5-6.0 (1H, m, 3-CH=CH), 5.9 (1H, d, J=5 Hz, 7-H), 6.15 (1H, d, J=11 Hz, 3-CH=CH), 6.89 (1H, m, OCHCH₃), 6.92 (1H, s, thiazole-H).

35 Anal. Calcd. for C₂₁H₂₃N₅O₈S_{2.4/5} [(CH₃)₂CH]₂O : C, 50.04; H, 5.57; N, 11.31 ; S, 10.35. Found : C, 49.73 ; H, 5.47 ; N, 10.90 ; S, 10.28.

Example 37

7 [(Z)-2-(2-Aminothiazol-4-yl)-2-(acetyloxyimino-acetamido)]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylic acid (Ia, R²=Ac, R³=H)

5 A suspension of 200 mg (1.30 m moles) of 1-hydroxy-1H-benzotriazole monohydrate, 631 mg (1.30 m moles) of 2-(2-tritylaminothiazol-4-yl)-2-acetoxyimino acetic acid* and 268 mg (1.30 m moles) of dicyclohexylcarbodiimide was stirred for 1 hr at 5°C. To the mixture was added
10 510 mg (1.26 m moles) of diphenylmethyl 7-amino-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate. The mixture was stirred for 5 hr at room temperature and diluted with 50 ml of AcOEt. The reaction mixture was washed with 1N HCl (25 ml), water (25 ml) and brine (25 ml), dried
15 over MgSO₄, and concentrated under diminished pressure. The residue was chromatographed on a column of silica gel (30 g) which was eluted with toluene-AcOEt (10/1). Fractions showing a spot at R_f 0.20 by TLC (10:1 toluene-AcOEt) were combined and evaporated in vacuo. The
20 residual oil (ca. 1.15 g) was dissolved in a mixture of 8 ml of 95 % TFA and 2 ml of anisole and the mixture was stirred for 1 hr in an ice-bath. The solution was concentrated under reduced pressure and triturated with isopropyl ether (40 ml) and n-hexane (10 ml) to give
25 432 mg of the crude product, which was purified by a column of Bondapak C-18, eluted with 30 % aqueous MeOH. Fractions showing a peak of retention time 6.9 min. (HPLC) were combined, concentrated and lyophilized to give 153 mg (27 %) of the title compound as an amorphous powder.
30 M.p. 155 °C (dec.). Estimated purity 65 % HPLC (Lichrosorb RP-18 4x300 mm, 3:7 MeOH-pH 7 buffer); retention time, 6.9 min.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 3260, 1775, 1765, 1665.

UV : $\lambda_{\max}$ (EtOH) in nm (ϵ) 230 (20100), 292 (12700).

NMR : δ (DMSO- d_6) in ppm 1.63 (3H, dd, $J=1$ & 7 Hz, =CHCH $\underline{3}$), 2.16 (3H, s, OAc), 3.55 (br.s, 2H, 2-H), 5.22 (1H, d, $J=5$ Hz, 6-H), 5.70 (1H, m, =CHCH $\underline{3}$), 5.76 (1H, dd, $J=5$ & 8 Hz, 7-H), 6.10 (1H, d, $J=11$ Hz, 3-CH=CH-), 7.05 (1H, s, thiazole-H), 7.28 (2H, s, -NH $_2$), 9.80 (1H, d, $J=8$ Hz).

*Japan Kokai 59-184186 (10/19/84, Meiji Seika)

Example 38

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-acetoxy-
iminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate
(Ib, R²=AC, R³=H, R⁴=AX)

To a solution of 20 mg (0.05 m mole) of Ia (R²=Ac, R³=H) in 0.2 ml of dry DMF was added 6 mg (0.05 m mole) of K₂CO₃ and the mixture was stirred for 5 minutes at 5 °C. 1-Acetoxyethyl bromide (10 µl) was added to the mixture and the suspension was stirred for 1 hr at the same temperature. The reaction mixture was diluted with 5 ml of AcOEt, washed successively with water (2 ml x 3) and brine, dried over MgSO₄ and concentrated under reduced pressure. The residue was triturated with 10 ml of isopropyl ether to give the desired acetoxyethyl ester, which was filtered off and dried. Yield 15 mg (63 %). Spectral data of the product were consistent with those of the compound prepared in Example 36.

Example 39

Pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetmido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=R³=H, R⁴=PV)

To a stirred mixture of Ib (R²=R³=H) (200 mg, 0.49 m mole) and Na₂CO₃ (26 mg, 0.24 m mole) in dry dimethylacetamide (5 ml) was added at -5 °C pivaloyloxymethyl iodide (118 mg, 0.49 m mole) and the mixture was stirred for 45 min. Sodium carbonate (13 mg, 0.12 m mole) and the iodide (59 mg, 0.12 m mole) were added again to the mixture and the mixture was stirred at the same temperature. After 30 min., the mixture showing spots at R_f 0.60 (major), 0.70 (minor) and 0.80 (minor) by TLC (Merck Kieselgel 60 F₂₅₄, 20:1 MeCN-E₂O) was diluted with ethyl acetate (25 ml) and the solution was washed with water (x3) and a saturated NaCl solution, dried over MgSO₄ and evaporated to dryness. The residue was dissolved in a small amount of CHCl₃ and passed through a column of Kieselgel 60 (13 g), which was washed with CHCl₃ (50 ml) and eluted with 1:20 MeOH-CHCl₃ (150 ml). The fractions showing a spot at R_f 0.60 by TLC were combined and evaporated. The residue was dissolved in benzene and the solution was lyophilized to afford 63 mg (25 %) of the title compound. M.p. 101-104 °C. Estimated purity 80 %. HPLC (Develosil 4x100 mm, 3:2 MeCN-pH 7 phosphate buffer): retention time, 4.6 min.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1755, 1670, 1530, 1120.

UV : $\lambda_{\max}$ (MeOH) in nm (ϵ) 270 (12000).

NMR : δ (CDCl₃ + D₂O) in ppm 1.22 (9H, s, 3 x CH₃), 1.56 (3H, dd, J=1 & 7 Hz, =CHCH₃), 3.45 (2H, m, S-CH₂) 5.11 (1H, d, J=4 Hz, 6-H), 5.5-5.95 (4H, m, 7-H, =CHCH₃ & OCH₂O), 6.14 (1H, d, J=11 Hz, 3-CH=), 7.02 (1H, s, thiazole-H).

Example 40

Acetoxy 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxy-
iminoacetamidol-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate
 (Ib, $R^2=R^3=H, R^4=AM^*$)

- 5 To a stirred suspension of Ia($R^2=R^3=H$) (280 mg, 0.68 m mole) and Na_2CO_3 (36 mg, 0.34 m mole) in dry DMF (5 ml) was added at $-10^\circ C$ over 10 min. a solution of acetoxymethyl bromide in dry DMF (104 mg, 0.68 m mole/100 μl). After 30 min, additional Na_2CO_3 (18 mg, 0.17 m mole) and the bromide solution (52 mg, 0.34 m mole/50 μl) were
 10 added in small portions over 10 min. The mixture was stirred at the same temperature for 30 min. The reaction mixture showing four spots at R_f 0.10 (BMV-28232), 0.15, 0.60 and 0.75 by TLC (Merck Kieselgel 60 F₂₅₄, 10:1 MeCN-H₂O) was diluted with AcOEt (25 ml), washed with
 15 water (x3) and a saturated NaCl solution, dried over $MgSO_4$ and evaporated. The residue was dissolved in a small amount of $CHCl_3$ and charged on a column of Kieselgel 60 (18 g), which was washed with $CHCl_3$ (50 ml) and eluted with MeOH- $CHCl_3$ (1 : 20, 250 ml). The
 20 fractions showing a spot at R_f 0.60 by TLC were combined and evaporated in vacuo. The residue was dissolved in benzene and lyophilized to afford 45 mg (14 %) of the title compound. M.p. 107-110 $^\circ C$. Estimated purity 70 %.
- 25 HPLC (Lichrosorb 4x300 mm, 2:3 MeCN-H₂O): retention time, 6.0 min.

IR : ν_{max} (KBr) in cm^{-1} 1770, 1665, 1530, 1370, 1200, 1000, 985.

UV : λ_{max} (MeOH) in nm (ϵ) 268 (10900).

- 30 NMR : δ ($CDCl_3 + D_2O$) in ppm 1.65 (3H, s, $J=7$ Hz, $=CHCH_3$), 2.1 (3H, s, $COCH_3$), 3.43 (2H, br, SCH_2), 5.1 (1H, d, $J=5$ Hz, 6-H), 5.3-5.95 (4H, m, 7-H, $=CHCH_3$ & OCH_2O), 6.15 (1H, d, $J=11$ Hz, 3-CH=), 6.96 (1H, s, thiazole-H).

* AM= - CH_2OCOCH_3

87

- 88 -

Example 41

Diphenylmethyl 7-amino-3-[(E)-1-butenyl]-3-cephem-4-carboxylate hydrochloride (XIII (B), $R^3=CH_3$, $R^{4a}=CHPh_2$)

A mixture of diphenylmethyl 7-amino-3-[(Z)-1-butenyl]-3-cephem-4-carboxylate hydrochloride (from Example 6) (2.9 g, 6.5 m moles) and benzophenone (1.2 g, 6.5 m moles) in methanol (300 ml) was irradiated with a low pressure Hg lamp (2537 Å, 6W) at room temperature for 26 hr. The solvent was evaporated *in vacuo* and the residue was dissolved in chloroform. The solution was treated with carbon and filtered. The filtrate was diluted with ether to precipitate 2.2 g (76 %) of the title compound E isomer contaminated with 10 % of the Z isomer which was used for the next step without further purification.

IR : ν_{max} (KBr) in cm^{-1} 1780, 1720, 1625.

UV : λ_{max} (MeOH) in nm (ε) 298 (10200).

NMR : δ (DMSO- d_6) in ppm 0.97 (3H, t, $J=7$ Hz, CH_3), 2.15 (2H, m, CH_2CH_3), 3.84 (2H, br-s, 2-H), 5.15 (1H, d, $J=5$ Hz, 6-H), 5.30 (1H, d, $J=5$ Hz, 7-H), 6.65 (1H, d, $J=16$ Hz, 3-CH=), 6.97 (1H, s, OCH), 7.45 (10H, s, phenyl-H).

HPLC: Lichrosorb RP-18 (4x250 mm), 3:2 CH_3CN -pH 7 phosphate buffer, 2 ml/min. Retention time: Z isomer, 5.1 min ; E isomer, 6.7 min.

Example 42

Diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylate
(XIV (E), $R^2=R^3=CH_3$, $R^{4a}=CHPh_2$)

A suspension of crude diphenylmethyl 7-amino-3-[(E)-1-butenyl]-3-cephem-4-carboxylate hydrochloride (1.97 g, 4.3 m moles) in AcOEt (30 ml) was shaken with aqueous $NaHCO_3$ to give a clear two-layer solution. The organic layer was separated, washed with water and then an aqueous saturated NaCl solution, dried over $MgSO_4$ and concentrated in vacuo. The residue was dissolved in DMF (20 ml). To the solution was added 1-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetoxy]benzotriazole (2.07 g, 6.5 m moles). The mixture was stirred at room temperature for 1 hr and diluted with AcOEt (100 ml). The diluted solution was washed with aqueous $NaHCO_3$, water and aqueous NaCl, successively, dried over $MgSO_4$ and evaporated in vacuo. The residue was chromatographed on a silica gel column (50 g) and eluted with 2:1 toluene-ethyl acetate to yield 1.58 g (61 %) of the title compound.

IR : ν_{max} (KBr) in cm^{-1} 1770, 1720, 1670.

UV : λ_{max} (MeOH) in nm (ϵ) 297 (18800).

NMR : δ ($CDCl_3 + D_2O$) in ppm 0.97 (3H, t, $J=7$ Hz, CH_2CH_3), 2.12 (2H, m, CH_2CH_3), 3.52 (2H, s, 2-H), 4.00 (3H, s, OCH_3), 5.10 (1H, d, $J=4.5$ Hz, 6-H), 5.93 (1H, d, $J=4.5$ Hz, 7-H), 5.7-6.3 (1H, m, $=CH-CH_2$), 6.74 (1H, s, thiazole-H), 6.96 (1H, s, OCH), 7.25 (10H, s, phenyl-H).

89

- 88 -

Example 43

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylic acid (Ia (E), $R^2=R^3=CH_3$)

A mixture of diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylate (650 mg, 1.1 m moles), TFA (3 ml) and anisole (1 ml) was stirred at 5 °C for 30 min and diluted with isopropyl ether. The resulting precipitate was collected by filtration. It was dissolved in formic acid (3 ml) and chromatographed on a column of the packing (100 ml) of a PrepPAK cartridge (Waters), which was washed with water and then eluted with 30 % methanol. The eluate was monitored by HPLC and the desired fractions were combined, concentrated and lyophilized to give 277 mg (59 %) of the title compound*. M.p. >170 °C (grad. dec.). Estimated purity 90 %.

IR : ν_{max} (KBr) in cm^{-1} 1770, 1660.

UV : λ_{max} (pH 7 phosphate buffer) in nm (ε) 232 (15700), 292 (22400).

NMR : δ ($D_2O + NaHCO_3$) in ppm 1.18 (3H, t, $J=7$ Hz, CH_2CH_3), 2.30 (2H, m, CH_2CH_3), 3.83 (2H, s, 2-H), 4.15 (3H, s, OCH_3), 5.37 (1H, d, $J=5$ Hz, 6-H), 5.92 (1H, d, $J=5$ Hz, 7-H), 5.9-6.4 (1H, m, $=CHCH_2$), 5.66 (1H, d, $J=16$ Hz, 3-CH=), 7.18 (1H, s, thiazole-H).

Anal. Calcd. for $C_{17}H_{19}N_5O_5S_2 \cdot 1/2H_2O$: C, 45.73 ; H, 4.51 ; N, 15.69 ; S, 14.36. Found: C, 45.63 ; H, 4.28 ; N, 15.33 ; S, 14.27.

*The 3-trans-butenyl cephalosporin Ia (E, $R^2=R^3=CH_3$), which was identical with that described in Example 15.

Example 44

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy-iminoacetamido]-3-[(E)-1-butenyl]-3-cephem-4-carboxylate
(Ib (E), $R^2=R^3=CH_3, R^4=AX$)

A mixture of Ia (E) ($R^2=R^3=CH_3$) (438 mg, 1 m mole) and K_2CO_3 (207 mg, 1.5 m moles) in DMF (10 ml) was treated with 1-acetoxyethyl bromide (250 mg, 1.5 m moles) by a similar procedure to that described in Example 16 to give 350 mg (67 %) of the desired AX ester, which was identical with that in Example 16. M.p. 110-115 °C. Estimated purity, 90 % by HPLC.

IR : ν_{max} (KBr) in cm^{-1} 1760 (br.), 1670, 1610.

UV : λ_{max} (MeOH) in nm (ϵ) 232 (16600), 298 (19300).

NMR : δ ($CDCl_3$) in ppm 1.05 (3H, t, $J=7$ Hz, CH_2CH_3), 1.54 (3H, d, $J=6$ Hz, $CHCH_3$), 2.08 (3H, s, $COCH_3$), 2.0-2.4 (2H, m, $-CH_2CH_3$), 3.57 (2H, s, 2-H), 4.05 (3H, s, OCH_3), 5.07 (1H, d, $J=5$ Hz, 6-H), 5.8-6.3 (2H, m, 7-H & $=CHCH_2-$), 6.86 (1H, s, thiazole-H), 6.8-7.1 (2H, m, OCH & 3-CH=)

Anal. Calcd. for $C_{21}H_{25}N_5O_7S_2 \cdot 1/4 [(CH_3)_2CH]_2O$: C, 49.21 ; H, 5.23 ; N, 12.75 ; S, 11.68. Found : C, 49.44 ; H, 5.28 ; N, 12.24 ; S, 11.70.

Example 45

7-Amino-3-[(E)-1-propenyl]-3-cephem-4-carboxylic acid
(XIII (E), $R^3=R^{4a}=H$)

A solution of 7-amino-3-[(2)-1-propenyl]-3-cephem-4-carboxylic acid* (1.2 g, 5 m moles) and benzophenone (900 mg, 5 m moles) in methanol (800 ml) containing 1 ml of 6N hydrochloric acid was irradiated with low-pressure Hg lamp (2537 Å, 6W) at room temperature for 44 hrs. The reaction mixture was evaporated to dryness and the residue was distributed in a mixture of 0.15N HCl (200 ml) and ether (200 ml). The aqueous layer was separated, treated with active carbon and filtered. The filtrate was adjusted to pH 3 with a dilute NaOH solution and cooled to give a precipitate. It was collected by filtration and washed with water and acetone to give 476 mg of the title compound E isomer, melting at 245 °C (grad. dec.). The second crop (195 mg) was obtained by concentrating the filtrate to 30 ml. Total yield 671 mg (56 %). The product contained less than 5 % of the corresponding Z isomer.

IR : $\nu_{\max}$ (KBr) in cm^{-1} 1800, 1620, 1540, 1420, 1360.

UV: $\lambda_{\max}$ (pH 7 phosphate buffer) in nm (ϵ) 292 (15000).

NMR : δ ($\text{D}_2\text{O} + \text{Na}_2\text{CO}_3$) in ppm 1.78 (3H, d, $J=6$ Hz, $=\text{CH}-\text{CH}_3$), 3.62 (2H, s, 2-H), 5.03 (1H, d, $J=4.5$ Hz, 6-H), 5.3-5.2 (2H, m, $=\text{CH}$ & 7-H), 6.52 (1H, d, $J=16$ Hz, 3-CH=C).

Anal. Calcd. for $\text{C}_{10}\text{H}_{12}\text{N}_2\text{O}_3\text{S} \cdot 1/2\text{H}_2\text{O}$: C, 48.18 ; H, 5.25 ; N, 11.24 ; S, 12.86. Found : C, 47.88 ; H, 4.83 ; N, 10.79 ; S, 12.83.

*A 4:1-mixture of Z and E isomers.

Example 46

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-
[(E)-1-propenyl]-3-cephem-4-carboxylic acid (Ia (E),
 $R^2=CH_3, R^3=H$

5 To a stirred solution of 7-amino-3-trans-propenyl
derivatives XIII ($E, R^3=R^{4a}=H$) (720 mg, 3 m moles) and
sodium bicarbonate (504 mg, 6 m moles) in 50 % DMF (60 ml)
was added 1-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-
10 acetoxyl]benzotriazole (954 mg, 3 m moles) and the mixture
was stirred for 30 min. An additional amount of the
active ester (1.81 g, 6 m moles) was added in four
portions at 30-min intervals. The mixture was stirred
for additional 2 hr at room temperature and passed
15 through a column packed with the packing of prepPAK-C₁₈
cartridge (300 ml, Waters). The column was washed with
water and then eluted successively with 10 % methanol
and 20 % methanol. Fractions of 20 % methanol eluate
showing a peak at retention time 5.57 min by HPLC* were
collected and evaporated to dryness. The residue was
20 dissolved in methanol and filtered. The filtrate was
concentrated to 5 ml and the residue was triturated with
a mixture of ether-isopropyl ether to give 805 mg (63 %)
of the title compound, melting at 180 °C (grad. dec.),
80 % pure by HPLC*.

25 IR : ν_{max} (KBr) in cm^{-1} 1770, 1670, 1630, 1540,
1380, 1040.

UV : λ_{max} (MeOH) in nm (E) 234 (17000), 293 (20000).

30 NMR : δ ($D_2O + Na_2CO_3$) in ppm 1.93 (3H, d-d, $J=6$
& 1.5 Hz, =CH-CH₃), 3.76 (2H, s, 2-H), 4.12 (3H, s, OCH₃),
5.32 (1H, d, $J=4.5$ Hz, 6-H), 5.86 (1H, d, $J=4.5$ Hz, 7-H),
5.8-6.3 (1H, m, =CH-CH₃), 6.61 (1H, d-d, $J=16$ & 1.5 Hz,
CH=C), 7.13 (1H, s, thiazole-H).

35 Anal. Calcd. for C₁₆H₁₇N₅O₅S₂ : C, 45.38 ; H, 4.05 ;
N, 16.54 ; S, 15.14. Found : C, 45.57, 45.41 ; H, 4.37,
4.29 ; N, 15.94, 15.76 ; S, 13.90, 13.62.

*Packing: Lichrosorb RP-18 (4x300 nm) Mobile phase:
MeOH-pH 7 buffer (35:65).

Example 47

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy-iminoacetamido]-3-[(E)-1-propenyl]-3-cephem-4-carboxylate
 (Ib (E), $R^2=CH_3$, $R^3=H$, $R^4=AX$)

- 5 To a stirred mixture of 317 mg (0.75 m mole) of the trans-propenyl cephalosporin Ia (E, $R^2=CH_3$, $R^3=H$) and 104 mg (0.75 m mole) of potassium carbonate in 5 ml of DMF was added at 0.5 °C a solution of 167 mg (1 m mole) of 1-acetoxyethyl bromide in 0.5 ml of DMF and the
- 10 mixture was stirred at 5 °C for 15 min. An additional amount of each of potassium carbonate (204 mg, 1.5 m moles) and the bromide solution in DMF (334 mg, 2 m moles/1 ml) was added in two portions over a period of 15 min to complete the reaction. The mixture was stirred at 5 °C for
- 15 additional 30 min and diluted with 150 ml of ethyl acetate. The dilute solution was washed with water and aqueous NaCl, dried with $MgSO_4$ and concentrated to dryness. The oily residue was dissolved in a small volume of $CHCl_3$ and chromatographed on a silica gel column (Merck Kieselgel
- 20 60, 40 g), which was washed with chloroform and eluted with chloroform-methanol (50:1). The desired fractions showing a spot at R_f 0.40 by TLC (silica gel, chloroform-methanol, 10:1) and a peak at retention time 7.7 min by HPLC (acetonitrile-pH 7 buffer, 1:1), were collected and
- 25 evaporated to dryness to give an oily residue, which was triturated with a mixture of ether and isopropyl ether to give 270 mg (70.5 %) of the desired title ester, melting at 140 °C (dec.). Estimated purity 80 % by HPLC.
- IR : ν_{max} (KBr) in cm^{-1} 1770, 1670, 1620, 1540, 30 1380, 1210, 1100, 1070, 1040.
- UV : λ_{max} (MeOH) in nm (ϵ) 234 (17000), 297 (19000).
- NMR : δ ($CDCl_3$) in ppm 1.53 (3H, d, $J=5$ Hz, C- CH_3), 1.86 (3H, d, $J=6$ Hz, $CH=CH-CH_3$), 2.08 (3H, s, $OCOCH_3$), 3.55 (2H, br-s, 2-H), 4.05 (3H, s, OCH_3), 5.07 (1H, d, $J=4.5$ Hz, 6-H), 5.38 (2H, br-s, NH_2), 5.95 (1H, d, $J=4.5$ Hz, 7-H), 5.7-6.2 (1H, m, $CH=CH-CH_3$), 6.31 (1H, s, thiazole-H), 35 6.9-7.1 (2H, m, $CH-CH_3$ & $CH=CH-CH_3$), 7.55 (1H, d, $J=3$ Hz, NH).

Example 48

Diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(triphenylphosphoranylidene)methyl]-3-cephem-4-carboxylate (VII, R^{2a} = CH₃)

5 A solution of diphenylmethyl 7-[(Z)-2-trityl-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(triphenylphosphonio)methyl]-3-cephem-4-carboxylate iodide* (3.0 g, 2.5 m moles) in dichloromethane (40 ml) was shaken with 1N NaOH (10 ml) until the spot of the starting material disappeared on TLC (silica gel, 10 CHCl₃-MeOH=10:1). Organic layer was separated and concentrated under reduced pressure. The residue was triturated with n-hexane and the product was collected by filtration to give 2.5 g (93%) of the title compound.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1760, 1740, 1560.

15 UV : $\lambda_{\max}$ (CH₂Cl₂) in nm (E) 310 (8800), 388 (15000).

* US 4,486,586, Column 33, Preparation No.17, Compound VIII-1.

Example 49

Diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[3-(Z)-acetoxy-1-propenyl]-3-cephem-4-carboxylate (VIII, $R^{2a}=CH_3$, $R^3=OAc$)

5 A mixture of diphenylmethyl 7-[(Z)-2-(2-trityl-
aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(triphenyl-
phosphoranylidene)methyl-3-cephem-4-carboxylate (2.13 g,
2.9 m moles) and acetoxyacetaldehyde¹ (0.61 g, 6.0 m
moles) in dichloromethane (10 ml) was stirred for 3 hr
at room temperature. The mixture was concentrated under re-
10 duced pressure and the residue was chromatographed on
a column of silica gel. The column was eluted with
n-hexane- $CHCl_3$ (1:2) and the fractions containing the
desired product were combined. Evaporation of the
solvent under reduced pressure afforded 1.0 g (56%)
15 of the title compound.

IR : ν_{max} (liq.) in cm^{-1} 1785, 1735, 1675, 1430,
1230, 1180.

NMR : δ (CCl_4) in ppm 6.08 (1H, d, $J=13$ Hz).

1) J. Corbet and C. Benezra, J. Org. Chem, 46, 1141 (1981).

Example 50

Diphenylmethyl 7-amino-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (XIII, R³ = OAc)

To a cooled mixture of LiBr (8.6 g, 0.1 mole) in dry DMF (40 ml) were successively added a solution of diphenylmethyl 7-benzylideneamino-3-[(triphenylphosphoranylidenemethyl)-3-cephem-4-carboxylate (XI) (7.3 g, 10 m moles) in dry methylene chloride (200 ml) and acetoxyacetaldehyde (3.06 g, 0.03 mole), and the mixture was stirred at room temperature for 44 hrs. After concentration to 50 ml, the oily residue was diluted with ethyl acetate and the solution was washed with water, a saturated NaCl solution, dried over MgSO₄ and concentrated to 100 ml. To the stirred concentrate was added a solution of the Girard T reagent (5 g, 0.03 mole) in methanol (100 ml) containing 1 ml of acetic acid and the mixture was stirred at room temperature for 40 min. After evaporation of the solvent, the residue was dissolved in 300 ml of ethyl acetate and the solution was washed with sodium bicarbonate solution, water, a saturated NaCl solution and dried with MgSO₄. Evaporation of the solvent gave an oily residue which was chromatographed on a silica gel column (Merck Kiesel gel 60, 100 g) by eluting with chloroform. The eluate was monitored by TLC (chloroform:methanol=30:1) and the fractions showing a spot at R_f 0.30 were combined and concentrated to afford an oily residue, which was triturated with ether-isopropyl ether to give 2.8 g (60%) of the title compound, melting at 130-135°C (dec.)

97

- 22a -

IR : $\nu_{\max}$ (KBr) in cm^{-1} 1770, 1720, 1390, 1370, 1220, 1100.

UV : $\lambda_{\max}$ (MeOH) in nm (ϵ) 286 (7500).

NMR: δ (CDCl_3) in ppm 1.83 (2H, br. s, NH_2), 2.02
5 (3H, s, COCH_3), 3.27 (1H, d, $J=18$ Hz, 2-H), 3.65 (1H,
d, $J=18$ Hz, 2-H), 3.9-4.9 (2H, m, CH_2OAc) 4.78 (1H, d,
 $J=4.5$ Hz, 6-H), 5.02 (1H, d, $J=4.5$ Hz, 7-H), 5.3-5.8

(1H, m, =CH-CH₂-), 6.27 (1H, d, J=11 Hz, CH=CH-CH₂),
6.97 (1H, s, CH-Ph), 7.2-7.6 (10H, m, phenyl H).

Anal. Calcd. for C₂₅H₂₄N₂O₅S : C, 64.64; H, 5.21;
N, 6.03; S, 6.90. Found: C, 64.79; H, 5.33; N, 5.89;
S, 6.94.

Example 51

Diphenylmethyl 7- [(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido] -3- [(Z)-3-acetoxy-1-propenyl] -3-cephem-4-carboxylate (XIV, R³=OAc)

A mixture of diphenylmethyl 7-amino-3- [(Z)-3-acetoxy-1-propenyl] -3-cephem-4-carboxylate (2.32 g, 5 m moles) and benzotriazol-1-yl (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetate (1.9 g, 6 m moles) in 100 ml of dry THF was stirred at room temperature for 20 hr and the solvent was evaporated to dryness. After extraction with ethyl acetate (200 ml), the solution was washed with aqueous sodium bicarbonate, a saturated NaCl solution and water, dried with MgSO₄ and concentrated to give an oily residue, which was chromatographed on a silica gel column (Kiesel gel 60, 80 g Merck), by eluting successively with chloroform and chloroform-methanol (50:1). The desired fractions eluted with chloroform-methanol (50:1), were combined and concentrated to give a residue which was triturated with ether-isopropyl ether to give 1.97 g (61%) of the title compound, melting at 120°C (grad. dec.).

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1730, 1670, 1610, 1530, 1370, 1220, 1030.

UV : $\lambda_{\max}$ (MeOH) in nm (ϵ) 286 (14000).

NMR : δ (CDCl₃) in ppm 1.97 (3H, s, COCH₃), 3.42 (2H, s, 2-H), 4.02 (3H, s, OCH₃), 5.15 (1H, d, J=4.5 Hz, 6-H), 6.03 (1H, d-d, J=4.5 & 9 Hz, 7-H), 6.27 (1H, d, J=11 Hz, CH=CH-CH₂), 6.78 (1H, s, thiazole-H), 6.94 (1H, s, CHPh), 7.2-7.6 (10H, m, phenyl-H), 8.03 (1H, d, J=9 Hz, NH).

Example 52

7-[(Z)-2-(Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylic acid
(Ia, $R^2 = \text{CH}_3$, $R^3 = \text{OAc}$)

A) From XIV ($R^3 = \text{OAc}$) ——— A mixture of diphenyl-
5 methyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyimino-
acetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-
carboxylate (1.88 g, 2.9 m moles), 3 ml of anisole and
9 ml of TFA was stirred at room temperature for 10 min
and the mixture was concentrated to 5 ml. After
10 dilution with 50 ml of ether and 100 ml of isopropyl
ether, the resulting precipitate was collected by
filtration to give 1.5 g of crude trifluoroacetate
of Ia ($R^2 = \text{CH}_3$, $R^3 = \text{OAc}$). It was chromatographed on a
column packed with the packing of prepPAK- C_{18} cartridge
15 (400 ml, Waters), which was successively eluted with
water and 20% methanol. The desired fractions eluted
with 20% methanol were collected and concentrated to
give a solid, which was dissolved in 100 ml of methanol
and the solution was treated with active carbon and
20 concentrated to 10 ml. To the chilled concentrate
was added ether (200 ml) and the resulting precipitate
was collected by filtration, washed with ether and
dried in vacuo over P_2O_5 to give 938 mg (67%) of the
title compound, melting at 160°C (grad. dec.).

25 IR : ν_{max} (KBr) in cm^{-1} 1770, 1720, 1670, 1620,
1530, 1370, 1230, 1030.

UV : λ_{max} (pH 7 phosphate buffer) in nm (ϵ) 231
(17000), 284 (16000).

NMR : δ ($\text{D}_2\text{O} + \text{Na}_2\text{CO}_3$) in ppm 2.22 (3H, s, COCH_3),
30 3.47 (1H, d, $J=18$ Hz, 2-H), 3.76 (1H, d, $J=18$ Hz, 2-H),
4.13 (3H, s, OCH_3), 5.39 (1H, d, $J=4.5$ Hz, 6-H), 5.92
(1H, d, $J=4.5$ Hz, 7-H), 6.36 (1H, d, $J=11$ Hz, $\text{CH}=\text{CH}-$
 CH_2), 7.14 (1H, s, thiazole-H).

Amal. Calcd. for $\text{C}_{18}\text{H}_{19}\text{N}_5\text{O}_7\text{S}_2 \cdot 1/2\text{H}_2\text{O}$: C, 44.07;
35 H, 4.11 ; N, 14.28 ; S, 13.07. Found: C, 44.29; H,
4.07; N, 13.98 ; S, 13.03.

B) From VIII ($R^{2a} = CH_3$, $R^3 = OAc$) - Diphenylmethyl
7- [(Z)-2-(tritylaminothiazol-4-yl)-2-methoxyimino-
acetamido-3-[(Z)-3-acetoxy-1-propenyl]methyl-3-4-
5 carboxylate (1.0 g, 1.12 m moles) was dissolved in 85 %
formic acid (5 ml) and the solution was stirred for 2 hr
at room temperature. Hydrochloric acid (0.1 ml) was
added and the stirring was continued for further 2 hr.
After removal of excess formic acid by evaporation, the
mixture was triturated with isopropyl ether to
10 precipitate the crude product, which was collected by
filtration and purified by chromatography to give 154 mg
(31 %) of the title compound, which was identical with
that obtained from the procedure A.

Example 53

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy-iminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, $R^2=CH_3$, $R^3=OAc$, $R^4=AX$)

5 To a cooled and stirred solution of Ia ($R^2=CH_3$, $R^3=OAc$) (362 mg, 0.75 m mole) in DMF (5 ml) were added K_2CO_3 (312 mg, 2.25 m moles) and a solution of 1-acetoxyethyl bromide (501 mg, 3 m moles) in DMF (1.5 ml) in three portions at 15 minute intervals, and the mixture
10 was stirred for additional 30 minutes. After dilution with ethyl acetate (200 ml), the solution was washed with water, a saturated NaCl solution, dried and evaporated to dryness. The oily residue was purified by chromatography on a silica gel column (Merck Kiesel
15 gel 60, 40 g) by eluting successively with chloroform and chloroform-methanol (50:1). The fractions showing a peak at retention time 6.1 min by HPLC* were collected and evaporated to dryness to give a residue which was triturated with ether to give 236 mg (68 %) of the title
20 compound. Estimated purity 60 %. This compound contained ca. 25 % of Δ^2 isomer as an impurity. M.p. 110 °C (grad. dec.).

IR : ν_{max} (KBr) in cm^{-1} 1780, 1760, 1740, 1670, 1610, 1530, 1370, 1230, 1070, 1030.

25 UV : λ_{max} (MeOH) in nm (ϵ) 268 (15000).

NMR : δ ($CDCl_3$) in ppm 1.51 (3H, d, $J=6$ Hz, $CH-CH_3$), 2.04 (3H, s, $COCH_3$), 2.08 (3H, s, $COCH_3$), 3.03 and 3.60 (1.5H, ABq, $J=18$ Hz, 2-H), 4.05 (3H, s, OCH_3), 6.17 (0.3H, s, Δ^2-H), 6.26 (1H, d, $J=11$ Hz, $CH=CH-CH_2$).

30 *HPLC (Lichrosorb RP-18, 4x300 mm, 50 % acetonitrile-buffer (pH 7)).

Example 54

Diphenylmethy 7-amino-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (XIII (E), $R^3=H$, $R^{4a}=-CHPh_2$)

To a solution of diphenylmethyl 7-amino-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (2.7 g, 5.8 m moles) and acetophenone (720 mg, 6 m moles) in methanol (1 L) was added 1N hydrochloric acid (6 ml). The solution was irradiated with low-pressure Hg lamp (2537 Å, 6W) under stirring at room temperature for 22 hrs and evaporated to dryness. The residue was dissolved in ethyl acetate (300 ml) and the solution was washed with aqueous sodium bicarbonate, water, a saturated NaCl solution and dried with $MgSO_4$. After evaporation of the solvent, the residue was chromatographed on a silica gel column (Merck Kiesel gel 60, 100:g) by eluting with chloroform. The fractions showing a spot at R_f 0.45 by TLC (chloroform: methanol = 30:1) were combined and concentrated to give a residue. Trituration of the residue with ether gave 910 mg (34 %) of the title compound, melting at 157 °C (dec.)

The latter fraction showing a spot at 0.40 on TLC gave 583 mg (22 %) of the starting Z isomer.

IR : ν_{max} (KBr) in cm^{-1} 1760, 1730, 1710, 1360, 1240, 1210, 1090.

UV : λ_{max} (MeOH) in nm (ϵ) 301 (15000).

NMR : δ ($CDCl_3$) in ppm 1.8 (2H, br.s, NH_2), 2.02 (3H, s, $COCH_3$), 3.56 (2H, s, 2-H), 4.73 (1H, d, $J=4.5$ Hz, 6-H), 4.95 (1H, d, $J=4.5$ Hz, 7-H), 6.87 (1H, d, $J=16$ Hz, $CH=CH-CH_2$), 7.05 (1H, s, $CHPh$), 7.3-7.6 (10H, m, Ph).

Anal. Calcd. for $C_{25}H_{24}N_2O_5S$: C, 64.64 ; H, 5.21 ; N, 6.03 ; S, 6.72. Found : C, 64.28 ; H, 5.21 ; N, 5.88 ; S, 6.82.

Example 55

Diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (XIV (E), $R^2=CH_3$, $R^3=OAc$, $R^{4a}=-CHPh_2$)

5 A mixture of Diphenylmethyl 7-amino-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (930 mg, 2 m moles) and 1-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetoxy] benzotriazole (954 mg, 3 m moles) in dry THF (40 ml) was stirred at room temperature for 4 hrs and the mixture was
10 concentrated to dryness. The residue was dissolved in ethyl acetate (100 ml) and the solution was washed with an aqueous sodium bicarbonate, water, a saturated NaCl solution and dried with $MgSO_4$. After evaporation of the solvent, the residue was chromatographed on a silica gel
15 column (Merck Kiesel gel 60, 40 g) by eluting successively with chloroform and chloroform-methanol (50 %). The desired fractions were collected and evaporated to dryness and the residue was triturated with ether to give 910 mg (70 %) of the title compound, melting at 110 °C (grad.dec.).

20 IR : ν_{max} (KBr) in cm^{-1} 1780, 1730, 1680, 1610, 1530, 1380, 1220.

UV : λ_{max} (MeOH) in nm (ϵ) 297 (22000).

NMR : δ ($CDCl_3$) in ppm 1.99 (3H, s, $COCH_3$), 3.56 (2H, s, 2-H), 4.04 (3H, s, OCH_3), 4.52 (2H, d, $J=6$ Hz, CH-CH- $\underline{CH_2}$), 5.08 (1H, d, $J=4.5$ Hz, 6-H), 5.97 (1H, d-d, $J=8$ & 4.5 Hz, 7-H), 5.7-6.2 (1H, m, CH=CH- $\underline{CH_2}$), 6.83 (1H, s, thiazole-H), 6.96 (1H, s, CHPh).

Example 56

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylic acid
 (Ia (E), $R^2=CH_3$, $R^3=OAc$)

5 A mixture of diphenylmethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (870 mg, 1.34 m moles) and anisole (0.8 ml) was dissolved in 2.4 ml of tri-fluoroacetic acid and the solution was stirred at room
 10 temperature for 15 min. The reaction mixture was worked up and purified by a similar procedure to that described in Example 52 (procedure A) to give 429 mg (66 %) of the title compound, melting at 180 °C (grad. dec.).

IR : ν_{max} (KBr) in cm^{-1} 1770, 1730, 1670, 1630,
 15 1530, 1370, 1240, 1030.

UV : λ_{max} (pH 7 phosphate buffer) in nm (ϵ) 231 (17000), 292 (26000).

NMR : δ ($D_2O + Na_2CO_3$) in ppm 2.20 (3H, s, $COCH_3$),
 3.75 (2H, s, 2-H), 4.10 (3H, s, OCH_3), 4.75 (2H, s,
 20 CH_2OAc), 5.32 (1H, d, $J=4.5$ Hz, 6-H), 5.88 (1H, d, $J=4.5$ Hz, 7-H), 5.9-6.3 (1H, m, $CH=CH-CH_2$), 6.73 (1H, d, $J=16$ Hz, $CH=CH-CH_2$), 7.09 (1H, s, thiazole-H).

Example 57

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxy-iminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib (E), $R^2=CH_3$, $R^3=OAc$, $R^4=AX$)

To a stirred solution of Ia (E) ($R^2=CH_3$, $R^3=OAc$) (241 mg, 0.5 m mole) in dry DMF (4 ml) were added at 0-5°C K_2CO_3 (140 mg, 1 m mole) and a solution of 1-acetoxyethyl bromide (336 mg, 2 m moles) in DMF (2 ml) in four portions at 15-minute intervals, and the mixture was stirred at the same temperature for additional 1 hr. After dilution with ethyl acetate, the solution was washed with water and a saturated NaCl solution, dried with $MgSO_4$ and concentrated to dryness. The residue was chromatographed on a silica gel column (Merck Kiesel gel 60, 30 g) by eluting with chloroform and chloroform-methanol (50:1), successively. The desired fractions eluted with chloroform-methanol were collected and evaporated to dryness and the residue was triturated with ether to give 185 mg (65%) of the title compound, melting at 120°C (grad. dec.).

IR : ν_{max} (KBr) in cm^{-1} 1770, 1680, 1620, 1500, 1390, 1240, 1080, 1040.

UV : λ_{max} (MeOH) in nm (ϵ) 232 (18000), 295 (21000).

NMR : δ ($CDCl_3$) in ppm 1.56 (3H, d, $J=6$ Hz, $CH-CH_3$), 2.08 (6H, s, $COCH_3$), 3.6 (2H, br-s, 2-H), 4.06 (3H, s, OCH_3), 5.07 (1H, d, $J=4.5$ Hz, 6-H), 5.39 (2H, br-s, NH_2), 5.7-6.4 (2H, m, $CH=CHCH_2$ & 7-H), 6.81 (1H, s, thiazole-H), 7.56 (1H, d, $J=8$ Hz, NH).

Example 58

Diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trithyloxyiminoacetamido]-3-chloromethyl-3-cephem-4-carboxylate (IV, R^{2a}=Tr)

To a mixture of (Z)-2-(2-tritylaminothiazol-4-yl)-2-trithyloxyiminoacetic acid*) (6.71 g, 10 m moles) and 1-hydroxybenzotriazole mono hydrate (1.53 g, 11 m moles) in THF (50 ml) was added dicyclohexylcarbodiimide (2.06 g, 10 m moles) at 5 °C and the mixture was stirred for 2 hr at the same temperature and filtered to give a solution of active ester. A suspension of diphenylmethyl 7-amino-3-chloromethyl-3-cephem-4-carboxylate hydrochloride (4.51 g, 10 m moles) in ethyl acetate (50 ml) was washed with saturated NaHCO₃ solution (10 ml x3), water and dried. The solution was poured into the solution of active ester prepared above with stirring at 0 °C and the mixture was allowed to stand for 2 days at 5 °C. After evaporation, the residue was chromatographed on a column of silica gel (silica gel 60, 100 g) and the column was eluted with CHCl₃-n-hexane (2:1). The fractions containing desired product was concentrated under reduced pressure. Trituration of the residue with n-hexane gave 10.0 g (94 %) of the title compound as an amorphous powder.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780, 1720, 1680, 1490.

UV : $\lambda_{\max}$ (CH₂Cl₂) in nm (ε) 245 (23000).

NMR : δ (CDCl₃) in ppm 3.4 (2H, ABq, J=12 Hz, 2-H), 5.02 (1H, d, J=4 Hz, 6-H), 6.01 (1H, d-d, J=4 and 6 Hz, 7-H), 6.45 (1H, s, thiazole-H), 7.00 (1H, s, CHPh₂), 7.1-7.7 (40H, phenyl-H).

*) R. Bucourt et al., Tetrahedron, 34, 2233 (1978)

Example 59

Diphenylmethyl 7- [(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-(triphenylphosphoranylidene) methyl-3-cephem-4-carboxylate (VII, R^{2a}=Tr)

- A mixture of diphenylmethyl 7- [(Z)-2-(2-tritylamino-
- 5 thiazol-4-yl)-2-trityloxyiminoacetamido]-3-chloromethyl-3-cephem-4-carboxylate (9.9 g, 9.3 m moles) and NaI (11 g, 73 m moles) in acetone (100 ml) was stirred for 30 min at room temperature and concentrated under reduced pressure. The residue was diluted with ethyl
- 10 acetate (100 ml), and the mixture was washed with aqueous 10% Na₂S₂O₃ solution (50 ml x 2) and water. To the mixture was added triphenylphosphine (3.93 g, 15 m moles) and the mixture was stirred for 3 hr at room temperature. After evaporation, the residue was
- 15 triturated with isopropyl ether and the precipitate was collected by filtration to give the phosphonium salt (14.2 g). It was dissolved in CH₂Cl₂ (100 ml) and the solution was washed with 1N NaOH (ca. 50 ml) until the phosphonium salt was completely converted into the
- 20 ylide by monitoring with TLC (Merck silica gel 60 F₂₅₄, CHCl₃-MeOH, 10:1). The organic layer was separated, washed with water and concentrated under reduced pressure. The residue was triturated with isopropyl ether to give 12.0 g (94%) of the title compound.
- 25 IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1760, 1740, 1650, 1480.
 UV : $\lambda_{\max}$ (CH₂Cl₂) in nm (ε) 310 (9200),
 388 (16200).

Example 60

Diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (VIII, R^{2a}=Tr), R³=OAc)

A mixture of diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-(triphenylphosphoranylidene)methyl-3-cephem-4-carboxylate (2.58 g, 2 m moles) and acetoxyacetaldehyde *) (612 mg, 3 m moles) in dichloromethane (10 ml) was stirred overnight at room temperature and concentrated under reduced pressure.

The residue was chromatographed on a column of silica gel (Merck silica gel 60, 50 g) and the column was eluted with toluene-ethyl acetate (9:1). Evaporation of the fractions containing the desired product gave 1.0 g (45 %) of the title compound.

IR : $\nu_{\max}$ (KBr) in cm^{-1} 1780, 1730, 1680, 1520, 1220.

UV : $\lambda_{\max}$ (CH_2Cl_2) in nm (ϵ) 305 (12200).

NMR : δ (CDCl_3) in ppm 2.00 (3H, s, COCH_3), 3.20 (2H, ABq, $J=18$ Hz, 2-H), 5.1 (1H, d, $J=4$ Hz, 6-H), 6.20 (1H, d, $J=11$ Hz, =CH), 6.48 (1H, s, thiazole-H), 6.95 (1H, s, CHPh_2), 7.1-7.6 (40H, phenyl-H).

*) J. Corbet and C. Benezra, J. Org. Chem., 46, 1141 (1981)

Example 61

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylic acid
(Ia, R²=H, R³=OAc)

A mixture of diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (3.29 g, 2.94 m moles) and 85 % formic acid (15 ml) was stirred for 2 hr at room temperature. To the solution was added conc. hydrochloric acid (0.6 ml) and the mixture was stirred for 2hr. After evaporation of the solvent, the residue was triturated with isopropyl ether to give 1.2 g of a crude product, which was chromatographed on a column of C18-silica gel (20 mm x 200 mm) by eluting with 20 % MeOH. The fractions containing the desired product were combined and concentrated to a small volume under reduced pressure. Lyophilization of the concentrate afforded 412 mg (30 %) of the title compound, melting at 180°C (dec.). Estimated purity 60 %.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1760, 1620, 1530, 1370, 1240.

UV : $\lambda_{\max}$ (pH 7 phosphate buffer) in nm (ϵ) 279 (15300).

NMR : δ (DMSO-d₆) in ppm 2.00(3H, s, COCH₃), 4.50 (2H, d, J=8 Hz,

CH₂O), 5.15 (1H, d, J=4 Hz, 6-H), 6.30 (1H, d, J=12 Hz, =CH-), 6.65 (1H, s, thiazol-H), 7.00 (2H, s, NH₂), 9.40 (1H, d, J=8 Hz, 7-CONH), 11.30 (1H, s, =N-OH).

Example 62

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl-2-hydroxy-iminoacetamido)]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, R²=H, R³=OAc, R⁴=AX)

5 To a stirred solution of Ia (R²=H, R³=OAc) (280 mg, 0.6 m mole) in dry DMF (2 ml) was added at -5 °C Na₂CO₃ (105 mg, 1 m mole) and a solution of 1-acetoxyethyl bromide (396 mg, 2.37 m moles) in DMF (2 ml) in three portions at 20-minute intervals and the mixture was
10 stirred for additional 10 minutes. After dilution with ethyl acetate, the solution was washed with water and concentrated under reduced pressure. Trituration of the residue with isopropyl ether gave 195 mg of the crude product, which was chromatographed on a column of
15 silica gel (25 g). The column was eluted with chloroform containing 1 - 2 % methanol and the fractions containing the desired product were combined and evaporated under reduced pressure. Trituration of the residue with isopropyl ether gave 75 mg (23 %) of the product, melting
20 at 100 °C (dec.). Estimated purity 70 %.

IR : $\nu_{\max}$ (KBr) in cm⁻¹ 1780-1730, 1670, 1530, 1380, 1240.

UV : $\lambda_{\max}$ (CH₂Cl₂) in nm (ϵ) 249 (17300).

25 NMR : δ (CDCl₃) in ppm 1.0 (3H, d, J=5 Hz, CH-CH₃), 2.03 (3H, s, COCH₃), 2.05 (3H, s, COCH₃), 5.10 (1H, d, J=4 Hz, 6-H), 6.30 (1H, d, J=12 Hz, =CH-), 6.95 (1H, s, thiazole-H).

Compound 33, Example 63

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-[(E)-1-propenyl]-3-cephem-4-carboxylic acid (Ia(E), R² = H, R³ = H)

A mixture of crude VIII (R^{2a} = Tr, R³ = H) containing 20 % of its E isomer (9.2 g, 8.7 mmol) in 85 % HCOOH (60 ml) was stirred for 1 hr at room temperature and evaporated in vacuo. The residue was treated with 90 % TFA (60 ml) for 1 hr at room temperature and poured into ice-water (300 ml). The insolubles were filtered off. The filtrate was chromatographed on a reverse phase column (Waters, prepPAK C18, 300 ml) and the column was eluted with 20 % MeOH. The polar fractions were combined, concentrated in vacuo and the residue was triturated with isopropyl ether to give 1.15 g (33 %) of the Z isomer (Ia, R² = R³ = H) and the less polar fractions gave 143 mg (4 %) of the title compound. mp >200 °C (dec). IR $\nu_{\max}$ (KBr) cm⁻¹ 1760, 1660, 1630, 1530. UV $\lambda_{\max}$ (pH 7 phosphate buffer) nm (ϵ) 223 (20000), 290 (21000). ¹H NMR (D₂O) δ 1.38 (3H, d, J=7.0 Hz), 3.73 (2H, br.s), 5.30 (1H, br.s), 5.85 (1H, d, J=5.0 Hz), 5.80-6.30 (1H, m), 6.57 (1H, d, J=16 Hz), 7.06 (1H, s)

Anal Calcd for C₁₅H₁₅N₅O₅S₂·1.5H₂O: C 41.28, H 4.16, N 16.05, S 14.65.

Found :

C 41.46, H 3.60, N 15.86, S 14.83.

Compound 40, Example 64

Pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, $R^2 = H$, $R^3 = OAc$, $R^4 = PV$)

To an ice-cooled mixture of Ia ($R^2 = H$, $R^3 = OAc$) (170 mg, 0.36 mmol) and Na_2CO_3 (20 mg, 0.19 mmol) in dry DMF (2 ml) was added pivaloyloxymethyl iodide (87 mg, 0.36 mmol) and the mixture was stirred for 10 min at the same temperature. Additional amount of pivaloyloxymethyl iodide (87 mg) and Na_2CO_3 (20 mg) was added and the mixture was stirred for additional 10 min. The mixture was diluted with ethyl acetate, washed with water and evaporated under reduced pressure. Chromatography of the residue on a silica gel column and elution with $CHCl_3$ -MeOH (1-2 %) gave the product as an amorphous powder. Yield 110 mg (52 %). mp 95-100 °C (dec). IR ν_{max} (KBr) cm^{-1} 1780, 1740, 1670, 1530. UV λ_{max} (EtOH) nm (ϵ) 280 (11400). 1H NMR ($CDCl_3$) δ 1.20 (9H, s, t-Bu), 2.0 (3H, s, OAc), 3.45 (2H, s, 2-H), 4.50 (2H, d, $J=7$ Hz, CH_2OAc), 5.10 (1H, d, $J=5$ Hz, 6-H), 5.3-6.0 (4H, m, 7-H, vinyl-H, CH_2OCO), 6.25 (1H, d, $J=12$ Hz, vinyl-H), 7.0 (1H, s, thiazole-H), 11.5 (1H, d, $J=8$ Hz, CONH)

Compound 41, Example 65

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylic acid (Ia(E), $R^2 = H$, $R^3 = OAc$)

a) Acylation

To a solution of 1-hydroxybenzotriazole (223 mg, 1.44 mmol) and (Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetic acid (1.06 g, 1.44 mmol) in THF (14 ml) was added DCC (300 mg, 1.44 mmol) and the mixture was stirred for 1 hr at 5 °C. Diphenylmethyl 7-amino-3-[(E)-acetoxy-1-propenyl]-3-cephem-4-carboxylate (670 mg, 1.44 mmol) was added to the mixture. After stirring for 4 hr at ambient temperature, the reaction mixture was filtered, diluted with ethyl acetate (50 ml) and washed with water. Concentration of the organic layer gave an oil, which was chromatographed on a column of silica gel. Elution with toluene-ethyl acetate (10:1) gave 1.607 g (99 %) of diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate as an amorphous powder. IR ν_{max} (KBr) cm^{-1} 1770, 1730. 1H NMR ($CDCl_3$) δ 2.0 (3H, s, OAc), 3.33 (2H, s, 2-H), 4.54 (2H, ABq, CH_2OAc), 5.04 (1H, d, $J=5$ Hz, 6-H), 6.0 (1H, m, vinyl-H), 6.02 (1H, dd, $J=5$ & 7 Hz, 7-H), 6.40 (1H, s, thiazole-H), 6.82 (1H, d, $J=15$ Hz, vinyl-H), 7.00 (1H, s, Ph_2CH), 7.3 (25H, s, Ph).

b) Deblocking

A mixture of diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetamido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (1.98 g, 1.75 mmol) in formic acid (20 ml) was stirred for 2 hr at room temperature. Conc. hydrochloric acid (0.16 ml, 1.92 mmol) was added

to the mixture and the mixture was stirred for 1 hr at room temperature. Filtration, and concentration of the filtrate, followed by trituration with IPE gave 975 mg of the crude product. Chromatography on a column of reversed phase silica gel and elution with 10 % MeOH in water and concentration of the fraction containing the desired product gave 418 mg (51 %) of the title compound as an amorphous powder. IR $\nu_{\max}$ (KBr) cm^{-1} 1765, 1730, 1650. UV $\lambda_{\max}$ (pH 7 phosphate buffer) nm (ϵ) 290 (23400). ^1H NMR ($\text{DMSO}-d_6$) δ 2.03 (3H, s, OAc), 3.65 (2H, ABq, 2-H), 4.61 (2H, ABq, CH_2OAc), 5.15 (1H, d, $J=5$ Hz, 6-H), 5.75 (1H, dd, $J=5$ & 8 Hz, 7-H), 6.15 (1H, m, vinyl-H), 6.65 (1H, s, thiazole), 6.85 (1H, d, $J=15$ Hz, vinyl-H), 7.05 (2H, s, NH_2).

Compound 44, Example 66

Pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetanido]-3-[(E)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib(E), $R^2 = H$, $R^3 = OAc$, $R^4 = PV$)

To a cooled and stirred mixture of Ia(E) ($R^2 = H$, $R^3 = OAc$) (200 mg, 0.43 mmol) and Na_2CO_3 (22.7 mg, 0.22 mmol) in DMF (2 ml) was added pivaloyloxymethyl iodide (91 mg, 0.43 mmol) and the mixture was stirred at 5 °C for 30 min. The reaction mixture was diluted with ethyl acetate (40 ml), washed with water and brine successively. The organic layer was dried over $MgSO_4$ and concentrated under diminished pressure. The crude product was chromatographed on a column of silica gel. Elution with $CHCl_3$ -MeOH (1-3 %) gave 123 mg (50 %) of the product as an amorphous powder. IR ν_{max} (KBr) cm^{-1} 3300, 2970, 1780, 1740. UV λ_{max} (MeOH) nm (ϵ) 296 (18500). 1H NMR ($DMSO-d_6$) δ 1.22 (9H, s, t-Bu), 2.08 (3H, s, OAc), 3.60 (2H, s, 2-H), 4.66 (2H, ABq, CH_2OAc), 5.06 (1H, d, $J=5$ Hz, 6-H), 5.85 (1H, dd, $J=5$ & 7 Hz, 7-H), 5.88 (2H, ABq, 4- CO_2CH_2), 6.0 (1H, m, vinyl-H), 7.00 (1H, s, thiazole), 7.1 (1H, d, $J=15$ Hz, vinyl-H).

117
~~117~~
Compound 46, Example 67

Acetoxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, $R^2 = \text{CH}_3$, $R^3 = \text{OAc}$, $R^4 = \text{AM}$)

To a cooled and stirred solution of 240 mg (0.5 mmole) of Ia ($R^2 = \text{CH}_3$, $R^3 = \text{OAc}$) in 4 ml of dry DMF were added at 0 °C K_2CO_3 (138 mg, 1 mmol) and a solution of acetoxymethyl bromide (306 mg, 2 mmole) in DMF (2 ml) in four portions at 15 minute-intervals and the mixture was stirred at 0-5 °C for additional 15 minutes. After dilution with 100 ml of ethyl acetate, the mixture was washed with water and a saturated NaCl solution, and dried over MgSO_4 . After removal of the solvent, the oily residue was purified by chromatography on a silica gel column (Merck, Kiesel gel 60, 30 g). The column was eluted with chloroform and chloroform-methanol (50:1 - 20:1) successively. The fractions eluted with chloroform-methanol (50:1) were collected and evaporated. The residue was triturated with ether-n-hexane to give 72 mg (26 %) of the desired product, melting at 90-95 °C (dec.) Estimated purity 80 %. IR ν_{max} (KBr) cm^{-1} 1770, 1730, 1670, 1610, 1530, 1370, 1230, 1030. UV λ_{max} (MeOH) nm (ϵ) 230 (17000), 287 (13000). ^1H NMR (CDCl_3) δ 2.02 (3H, s, OAc), 2.12 (3H, s, OCOCH_3), 3.33 (1H, d, $J=18$ Hz, 2-H), 3.60 (1H, d, $J=18$ Hz, 2-H), 4.04 (3H, s, OCH_3), 4.4-4.6 (2H, m, $\text{CH}_2\text{OCOCH}_3$), 5.12 (1H, d, $J=4.5$ Hz, 6-H), 5.38 (2H, br-s, NH_2), 5.82 (2H, s, COOCH_2OAc), 5.4-5.9 (1H, m, $\text{CH}=\text{CHCH}_2$), 5.98 (1H, dd, $J=8$ & 4.5 Hz, 7-H), 6.29 (1H, d, $J=11$ Hz, $\text{CH}=\text{CH}-\text{CH}_2$), 6.82 (1H, s, thiazole-H), 7.55 (1H, d, $J=8$ Hz, NH).

~~113~~ 18

Compound 63, Example 68

7-[(Z)-2-(2-Aminothiazol-4-yl)-2-acetoxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylic acid (Ia, R² = Ac, R³ = OAc)

a) Acylation

To a mixture of (Z)-2-(tritylaminothiazol-4-yl)-2-acetoxyiminoacetic acid (1.95 g, 4.0 mmol) and 1-hydroxybenzotriazole (600 mg, 4.0 mmol) in THF (14 ml) was added DCC (824 mg, 4.0 mmol) and the mixture was stirred for 1 hr in an ice bath. Diphenylmethyl 7-amino-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (1.30 g, 2.8 mmol) was added to the suspension and the mixture was stirred for 4 hrs at ambient temperature, filtered, and diluted with AcOEt (60 ml). The organic phase was washed with water, dried over MgSO₄, and concentrated under reduced pressure. The residue was chromatographed on a column on silica gel (Wakogel C200, 80 g), which was eluted with toluene-AcOEt (6:1). Fractions which contained the product were combined and concentrated in vacuo to give 2.01 g (77 %) of diphenylmethyl 7-[(Z)-2-(tritylaminothiazol-4-yl)-2-acetoxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (VIII, R^{2a} = Ac, R³ = OAc). IR $\nu_{\max}$ (KBr) cm⁻¹ 1780, 1730. ¹H NMR (CDCl₃) δ 2.0 (3H, s, CH₃CO), 2.15 (3H, s, CH₃CO), 3.45 (2H, ABq, 2-H), 4.20 (2H, ABq, CH₂OAc), 5.12 (1H, d, J=5 Hz, 6-H), 5.70 (1H, m, 3-CH=CH), 5.90 (1H, dd, J=5 & 7 Hz, 7-H), 6.26 (1H, d, J=12 Hz, 3-CH=CH), 6.95 (1H, s, thiazole), 7.30 (25H, s, phenyl).

b) Deblocking

A mixture of diphenylmethyl 7-[(Z)-2-(2-tritylaminothiazol-4-yl)-2-acetoxyiminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate

(3.2 g, 3.43 mmol) in TFA (20 ml) and anisole (5 ml) was stirred for 1 hr at 5 °C. Removal of the solvent followed by trituration with 100 ml of isopropyl ether gave 1.25 g of TFA salt. The crude product was purified by chromatography using a column of C18 Bondapak, which was eluted with water, 10 % MeOH in H₂O and 20 % MeOH in H₂O, successively. Appropriate fractions were combined, concentrated in vacuo and lyophilized to afford 395 mg (23 %) of the title compound. IR ν_{max} (KBr) cm⁻¹ 3300, 1770, 1670. UV λ_{max} (pH 7 phosphate buffer) nm (ϵ) 228 (20300), 284 (15300). ¹H NMR (DMSO-d₆) δ 2.0 (3H, s, CH₃CO), 2.15 (3H, s, CH₃CO), 4.51 (2H, ABq, CH₂-OAc), 5.22 (1H, d, J=5 Hz, 6-H), 5.60 (1H, m, 3-CH=CH), 5.80 (1H, dd, J=5 & 7 Hz, 7-H), 6.32 (1H, d, J=12 Hz, 3-CH=CH), 7.05 (1H, s, thiazole).


Compound 65, Example 69

1-Acetoxyethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-acetoxviminoacetamido]-3-[(Z)-3-acetoxy-1-propenyl]-3-cephem-4-carboxylate (Ib, $R^2 = \text{Ac}$, $R^3 = \text{OAc}$, $R^4 = \text{AX}$)

To a solution of Ia ($R^2 = \text{Ac}$, $R^3 = \text{OAc}$, 248 mg, 0.49 mmol) in 25 ml of dry DMF was added Na_2CO_3 (51 mg, 0.49 mmol) and 1-acetoxyethyl bromide (82 mg, 0.49 mmol) at -10°C . The mixture was stirred at 5°C for 30 min and 82 mg (0.49 mmol) of 1-acetoxyethyl bromide was added to the suspension. After being stirred for 30 min more, the reaction mixture was diluted with AcOEt (50 ml), washed with water (30 ml x 3) and brine, dried over MgSO_4 and evaporated under diminished pressure. The crude product was purified by silica gel chromatography eluted with 3 % MeOH in chloroform. Removal of the solvent from appropriate eluant followed by freeze-drying gave 157 mg (54 %) of the title compound, mp 125°C (dec). IR ν_{max} (KBr) cm^{-1} 3430, 3290, 1770, 1680. UV λ_{max} (pH 7 phosphate buffer) nm (ϵ) 228 (21900), 287 (12700). ^1H NMR ($\text{DMSO}-d_6$) δ 1.51 (3H, d, $J=6$ Hz, 4-COOCHCH₃), 2.02 (3H, s, AcO), 2.06 (3H, s, AcO), 2.22 (3H, s, AcO), 3.47 (2H, br.s, 2-H), 4.46 (1H, d, $J=6$ Hz, 4-COOCHCH₃), 4.55 (2H, ABq, CH₂OAc), 5.12 (1H, d, $J=5$ Hz, 6-H), 5.70 (1H, m, 3-CH=CH-), 5.95 (1H, dd, $J=5$ & 7 Hz, 7-H), 6.25 (1H, d, $J=12$ Hz, 3-CH=CH), 6.92 (1H, s, thiazole).

Compound 88, Example 70

(5-Methyl-2-oxo-1,3-dioxolen-4-yl)-methyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (Ib, R²



To an ice-cooled and stirred solution of Ib (R² = H, R³ = H) (512 mg, 1.25 mmol) in DMF (2 ml) were added sodium carbonate (238.5 mg, 4.5 mmol) and a solution of 4-bromomethyl-5-methyl-1,3-dioxolen-2-one (869 mg, 4.5 mmol) in DMF (6 ml) in three portions at 15 minute intervals. The mixture was diluted with ethyl acetate (50 ml), washed with water and brine, and dried over MgSO₄. The filtrate was concentrated in vacuo. The residue was dissolved in a small amount of chloroform and purified by a silica gel column chromatography. (Kiesel gel 60, 30 g). The desired fractions eluted with a mixture of chloroform and methanol (30 : 1) were combined, and concentrated in vacuo to give 182 mg (29 %) of the desired product. mp 115-120 °C (dec). IR $\nu_{\max}$ (KBr) cm⁻¹ 1820, 1770, 1735, 1530, 1210, 1190. UV $\lambda_{\max}$ (EtOH) nm (ϵ) 225 (sh19000), 287 (12000). ¹H NMR (CDCl₃ + D₂O) δ 1.62 (3H, d, J=6.0 Hz), 2.18 (3H, s), 3.45 (2H, br, s), 4.68 (2H, s), 5.10 (1H, d, J=5.5 Hz), 5.50-5.90 (1H, m), 5.85 (1H, d, J=5.5 Hz), 6.12 (1H, d, J=12 Hz), 6.95 (1H, s).

Compound 89, Example 71


1-Ethoxycarbonyloxyethyl 7-[(Z)-2-(2-aminothiazol)-4-yl]-2-hydroxyimino-acetamido]-3-[(Z)-1-propenyl]-3-cephem-4-carboxylate (Ib, $R^2 = H$, $R^3 = H$, $R^4 = CH_3CHOCOOEt$)

To a stirred solution of Ib ($R^2 = H$, $R^3 = H$, 256 mg, 0.625 mmol) in DMF (2 ml) were added sodium carbonate (40 mg, 0.625 mmol) and a solution of α -iododiethylcarbonate (183 mg, 0.625 mmol) in DMF (1 ml) at 0-5 °C. After the mixture was stirred for 20 min at 5 °C, sodium carbonate (40 mg) and a solution of α -iododiethylcarbonate (183 mg) were added and the mixture was stirred for 40 min. The mixture was diluted with ethyl acetate (50 ml), washed with water (50 ml x 2), dried over $MgSO_4$ and filtered. The filtrate was concentrated in vacuo. The residue was dissolved in a small amount of chloroform and purified by a silica gel column (Kiesel gel-60, 20 g). The desired fractions eluted with a mixture of chloroform and methanol (30 : 1) were combined and concentrated in vacuo to give 56 mg (17 %) of the desired product. mp 105-110 °C. IR ν_{max} (KBr) cm^{-1} 1760, 1525, 1370, 1270. UV λ_{max} (EtOH) nm (ϵ) 222 (20000), 286 (11000). 1H NMR ($CDCl_3 + D_2O$) δ 1.33 (3H, t, $J=7$ Hz), 1.57 (3H, d, $J=5$ Hz), 1.70 (3H, d, $J=7$ Hz), 3.45 (2H, br. s), 4.23 (2H, q, $J=7$ Hz), 5.10 (1H, d, $J=5.0$ Hz), 5.87 (1H, d, $J=5.0$ Hz), 5.50-6.00 (1H, m), 6.16 (1H, d, $J=12$ Hz), 6.92 (1H, q, $J=5$ Hz), 7.00 (1H, s).



CLAIMS

1. A compound of the formula




wherein

R^1 is hydrogen or an amino-protecting group
 R^2 is hydrogen, straight or branched chain alkyl having 1 to 4 carbon atoms, alkenyl or alkynyl having 2 to 4 carbon atoms, cycloalkyl having 3 to 6 carbon atoms, cycloalkylalkyl having 3 to 6 ring members and 4 to 10 carbon atoms, or alkanoyl having 2 to 4 carbon atoms,

R^3 is hydrogen, lower alkyl having 1 to 3 carbon atoms, lower alkoxy having 1 to 3 carbon atoms, lower alkanoyloxy having 2 to 3 atoms, and

R^4 is hydrogen, or a physiologically hydrolyzable ester group;

or a pharmaceutically acceptable acid addition salt, metal salt (when R^4 is H), or hydrate or other solvate thereof; whether in the nominal or a tautomeric form.



124 -

- 5 2. The compound of Claim 1 wherein R^1 is hydrogen and
 R^2 is hydrogen, methyl, ethyl, isopropyl, cyclo-
 propylmethyl, allyl, propargyl or acetyl.
3. The compound of Claim 2 wherein R^2 is hydrogen.
- 10 4. The compound of Claim 3 wherein R^3 is hydrogen.
5. The compound of Claim 4 wherein R^4 is hydrogen.
- 15 6. 7β -[(Z)-2-(2-
 aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-
 [(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.
7. 7β -[(Z)-2-(2-amino-
20 thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-
 prop-1-en-1-yl]-3-cephem-4-carboxylic acid.
8. The compound of Claim 4 wherein R^4 is acetoxymethyl.
- 25 9. Acetoxymethyl
 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
 acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-
 carboxylate.



- 5 10. Acetoxymethyl
7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
acetamido]-3- [(E)-prop-1-en-1-yl]-3-cephem-4-
carboxylate.
- 10 11. The compound of Claim 4 wherein R⁴ is 1-acetoxy-
ethyl.
12. 1-acetoxyethyl
7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
15 acetamido]-3- [(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
13. 1-acetoxyethyl
7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
acetamido]-3- [(E)-prop-1-en-1-yl]-3-cephem-4-
20 carboxylate.
14. The compound of Claim 4 wherein R⁴ is pivaloyloxy-
methyl.
- 25 15. Pivaloyloxy-
methyl 7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxy-
imino)acetamido]-3- [(Z)-prop-1-en-1-yl]-3-cephem-
4-carboxylate.
- 30 16. Pivaloyloxymethyl
7 β - [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
acetamido]-3- [(E)-prop-1-en-1-yl]-3-cephem-4-
carboxylate.



17. The compound of claim 3 wherein R^3 is acetoxy.
18. The compound of claim 17 wherein R^4 is hydrogen.
19. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid.
20. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid.
21. The compound of claim 17 wherein R^4 is acetoxymethyl.
22. Acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.
23. Acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.



24. The compound of claim 17 wherein R⁴ is
1-acetoxyethyl.

25. 1-acetoxyethyl
7β- [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
5 acetamido]-3- [(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.

26. 1-acetoxyethyl
7β- [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
10 acetamido]-3- [(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.

27. The compound of claim 17 wherein R⁴ is pivaloyloxy-
methyl.

28. Pivaloyloxymethyl
7β- [(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)
15 acetamido]-3- [(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.

29. Pivaloyloxymethyl
7β- [(Z)-2-(2-amino-thiazol-4-yl)-2-(hydroxyimino)
20 acetamido]-3- [(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.



30. The compound of claim 2 wherein R^2 is methyl.
31. The compound of claim 30 wherein R^3 is hydrogen.
32. The compound of claim 31 wherein R^4 is hydrogen.
33. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.
34. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.
35. The compound of claim 31 wherein R^4 is 1-acetoxyethyl.
36. 1-acetoxyethyl
 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
37. 1-acetoxyethyl
 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
38. The compound of claim 31 wherein R^4 is pivaloyloxy-methyl.



39. Pivaloyloxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]
-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
40. Pivaloyloxymethyl
5 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
41. The compound of claim 30 wherein R³ is methyl.
42. The compound of claim 41 wherein R⁴ is hydrogen.
43. 7 β -[(Z)-2-(2-
10 aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-
1-en-1-yl]-3-cephem-4-carboxylic acid.
44. 7 β -[(Z)-2-(2-
aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-
1-en-1-yl]-3-cephem-4-carboxylic acid.



- 130

5 45. The compound of Claim 41 wherein R⁴ is acetoxy-
methyl.

46. Acetoxymethyl
10 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-
carboxylate.

47. Acetoxymethyl
15 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-
carboxylate.



48. The compound of Claim 41 wherein R⁴ is 1-acetoxyethyl.
49. 1-acetoxyethyl
5 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate.
50. 1-acetoxyethyl
10 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate.
51. The compound of Claim 41 wherein R⁴ is pivaloyloxymethyl.
15
52. Pivaloyloxymethyl
20 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate.
53. Pivaloyloxy-
25 methyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate.



54. The compound of claim 41 wherein R^4 is 4-glycyloxy-benzoyloxymethyl.

55. 4-glycyloxy-benzoyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-but-1-en-1-yl]-3-cephem-4-carboxylate.

56. 4-glycyloxy-benzoyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-but-1-en-1-yl]-3-cephem-4-carboxylate.

57. The compound of claim 30 wherein R^3 is ethyl.

58. The compound of claim 57 wherein R^4 is hydrogen.

59. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(2-methoxyimino)acetamido]-3-[(Z)-pent-1-en-1-yl]-3-cephem-4-carboxylic acid.

60. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(2-methoxyimino)acetamido]-3-[(E)-pent-1-en-1-yl]-3-cephem-4-carboxylic acid.



61. The compound of claim 57 wherein R⁴ is
1-acetoxyethyl.
62. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
5 acetamido]-3-[(Z)-pent-1-en-1-yl]-3-cephem-4-carboxylate.
63. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-pent-1-en-1-yl]-3-cephem-4-carboxylate.
- 10 64. The compound of claim 57 wherein R⁴ is pivaloyloxymethyl.
65. Pivaloyloxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(Z)-pent-1-en-1-yl]-3-cephem-4-carboxylate.
- 15 66. Pivaloyloxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-pent-1-en-1-yl]-3-cephem-4-carboxylate.



67. The compound of claim 30 wherein R^3 is methoxy.
68. The compound of claim 67 wherein R^4 is hydrogen.
69. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid.
5
70. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid.
71. The compound of claim 67 wherein R^4 is 1-acetoxyethyl.
10
72. 1-acetoxyethyl
 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.
73. 1-acetoxyethyl
 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-methoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.
15
74. The compound of claim 67 wherein R^4 is pivaloyloxy-methyl.



75. Pivaloyloxy-
methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(Z)-3-methoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.
- 5 76. Pivaloyloxy-
methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-3-methoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.
77. The compound of claim 30 wherein R³ is acetoxy.
- 10 78. The compound of claim 77 wherein R⁴ is hydrogen.
79. 7 β -[(Z)-2-(2-
aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-
acetoxyp-1-en-1-yl]-3-cephem-4-carboxylic acid.



136

80. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylic acid.

5 81. The compound of claim 77 wherein R^4 is acetoxymethyl.

82. Acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.

10 83. Acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.

15 84. The compound of claim 77 wherein R^4 is 1-acetoxyethyl.



85. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(Z)-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.
- 5 86. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.
- 10 87. The compound of claim 77 wherein R⁴ is pivaloyloxy-
methyl.
88. Pivaloyloxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.
- 15 89. Pivaloyloxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)
acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-
carboxylate.
90. The compound of claim 2 wherein R² is acetyl.



91. The compound of claim 90 wherein R^3 is hydrogen.

92. The compound of claim 91 wherein R^4 is hydrogen.

5 93. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.

94. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.

10 95. The compound of claim 91 wherein R^4 is acetoxymethyl.

96. Acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetoamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

15 97. Acetoxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate.



98. The compound of claim 91 wherein R⁴ is 1-acetoxyethyl.

99. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
5 acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

100. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

101. The compound of claim 91 wherein R⁴ is pivaloyloxy-
10 methyl.

102. Pivaloyloxy-
methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

103. Pivaloyloxy-
15 methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

104. The compound of claim 91 wherein R⁴ is 5-methyl-2-
oxo-1,3-dioxolen-4-ylmethyl.



105. 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxylimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

106. 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxylimino)acetamido]-3-[(E)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

107. The compound of claim 90 wherein R^3 is acetoxy.

108. The compound of claim 107 wherein R^4 is hydrogen.

109. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxylimino)acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylic acid.

110. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxylimino)acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylic acid.

111. The compound of claim 107 wherein R^4 is acetoxymethyl.



112. Acetoxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-acetoxyimino)
acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-
carboxylate.
- 5 113. Acetoxymethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-
carboxylate.
- 10 114. The compound of claim 107 wherein R⁴ is
1-acetoxyethyl.
115. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)acetamido]-
3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-carboxylate.
- 15 116. 1-acetoxyethyl
7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
acetamido]-3-[(E)-3-acetoxyp-1-en-1-yl]-3-cephem-4-
carboxylate.
117. The compound of claim 107 wherein R⁴ is
pivaloyloxymethyl.
- 20 118. Pivaloyloxy-
methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxyimino)
acetamido]-3-[(Z)-3-acetoxyp-1-en-1-yl]-3-cephem-4-
carboxylate.



119. Pivaloyloxy-methyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.

5 120. The compound of claim 107 wherein R⁴ is 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl.

121. 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(Z)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.

122. 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(acetoxymino)acetamido]-3-[(E)-3-acetoxyprop-1-en-1-yl]-3-cephem-4-carboxylate.

123. The compound of claim 2 wherein R² is isopropyl.

124. The compound of claim 123 wherein R³ is hydrogen.

125. The compound of claim 124 wherein R⁴ is hydrogen.



126. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(isopropoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.
- 5 127. The compound of claim 124 wherein R^4 is 1-acetoxyethyl.
128. 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(isopropoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
- 10 129. The compound of claim 124 wherein R^4 is pivaloyloxymethyl.
130. Pivaloyloxy-methyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(isopropoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.
- 15 131. The compound of claim 2 wherein R^2 is allyl.
132. The compound of claim 131 wherein R^3 is hydrogen.
133. The compound of claim 132 wherein R^4 is hydrogen.



144

134. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(allyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.

5 135. The compound of claim 132 wherein R^4 is 1-acetoxyethyl.

136. 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(allyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

10 137. The compound of claim 132 wherein R^4 is pivaloyloxymethyl.

138. Pivaloyloxy-methyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(allyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

15 139. The compound of claim 2 wherein R^2 is ethyl.

140. The compound of claim 139 wherein R^3 is hydrogen.

141. The compound of claim 140 wherein R^4 is hydrogen.



- 145

142. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(ethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.

5 143. The compound of claim 140 wherein R^4 is 1-acetoxyethyl.

144. 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(ethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

10 145. The compound of claim 140 wherein R^4 is pivaloyloxymethyl.

15 146. Pivaloyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(ethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

147. The compound of claim 2 wherein R^2 is cyclopropylmethyl.

148. The compound of claim 147 wherein R^3 is hydrogen.

149. The compound of claim 148 wherein R^4 is hydrogen.



- 146

150. 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(cyclopropylmethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.

5 151. The compound of claim 148 wherein R^4 is 1-acetoxyethyl.

10 152. 1-acetoxyethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(cyclopropylmethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

153. The compound of claim 148 wherein R^4 is pivaloyloxymethyl.

15 154. Pivaloyloxymethyl 7β -[(Z)-2-(2-aminothiazol-4-yl)-2-(cyclopropylmethoxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

155. The compound of claim 2 wherein R^2 is propargyl.

156. The compound of claim 155 wherein R^3 is hydrogen.

20 157. The compound of claim 157 wherein R^4 is hydrogen.



- 147

158. 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(propargyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid.

5 159. The compound of claim 156 wherein R⁴ is 1-acetoxyethyl.

160. 1-acetoxyethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-(propargyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.

10 161. The compound of claim 156 wherein R⁴ is pivaloyloxymethyl.

15 162. Pivaloyloxymethyl 7 β -[(Z)-2-(2-aminothiazol-4-yl)-2-propargyloxyimino)acetamido]-3-[(Z)-prop-1-en-1-yl]-3-cephem-4-carboxylate.



148

163. A pharmaceutical antibacterial composition comprising an effective amount of a compound of claim 2 in association with a pharmaceutically acceptable substantially nontoxic carrier or excipient.

164. Medication comprising an antibacterially effective non-toxic dose of a compound claimed in claim 2, for use in a method for the treatment of a bacterial infection in a mammal caused by an organism sensitive to a substance claimed in claim 2, by administration of the medication to the infected mammal on a repetitive dosage regimen for a treatment period of sufficient duration to mitigate said infection.
